

# 1 **Disordered regions and folded modules in CAF-1 promote histone** 2 **deposition in *S. pombe***

3  
4 Fouad Ouasti<sup>1,2,4,8</sup>, Maxime Audin<sup>1,2,8</sup>, Karine Freon<sup>3,4,5</sup>, Jean-Pierre Quivy<sup>6</sup>, Mehdi Tachekort<sup>1,2</sup>,  
5 Elizabeth Cesard<sup>1,2</sup>, Aurélien Thureau<sup>7</sup>, Virginie Ropars<sup>1,2</sup>, Paloma F. Varela<sup>1,2</sup>, Gwenaelle Moal<sup>1,2</sup>,  
6 Ibrahim Soumana Amadou<sup>3,4,5</sup>, Aleksandra Uryga<sup>3,4,5</sup>, Pierre Legrand<sup>7</sup>, Jessica Andreani<sup>1,2</sup>, Raphael  
7 Guerois<sup>1,2</sup>, Geneviève Almouzni<sup>6</sup>, Sarah Lambert<sup>3,4,5\*</sup>, Françoise Ochsenbein<sup>1,2\*</sup>

8 <sup>1</sup>Institute Joliot, Commissariat à l'énergie Atomique (CEA), Direction de la Recherche Fondamentale (DRF),  
9 F91191 Gif-sur-Yvette, France

10 <sup>2</sup>Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay,  
11 91198, Gif-sur-Yvette cedex, France

12 <sup>3</sup>Institut Curie, PSL Research University, UMR3348, 91400 Orsay, France.

13 <sup>4</sup>Paris-Saclay University, 91400 Orsay, France.

14 <sup>5</sup>CNRS, UMR3348, 91400 Orsay France. Equipe Labellisée ligue contre le Cancer.

15 <sup>6</sup>Institut Curie, PSL Research University, CNRS, Sorbonne Université, Nuclear Dynamics Unit, Équipe Labellisée  
16 Ligue contre le Cancer, Paris, France.

17 <sup>7</sup>Synchrotron SOLEIL, HelioBio group, l'Orme des Merisiers, Départementale 128, 91190 Saint-Aubin, France.

18 <sup>8</sup>These author contributed equally

19 # Correspondence: [francoise.ochsenbein@cea.fr](mailto:francoise.ochsenbein@cea.fr) Phone: 33-1-69089679 Fax: 33-1-69084712;  
20 <mailto:Sarah.Lambert@curie.fr>

21

## 22 **Abstract**

23 Coupling histone deposition with DNA synthesis is important for genome and epigenome integrity in  
24 eukaryotes. Here, we reconstituted *SpCAF-1*, the major histone deposition factor linked to DNA  
25 synthesis in fission yeast and characterized its structure using NMR, SAXS and molecular modeling.  
26 We reveal the unfolded nature of the acidic domain, and how it folds upon histone binding, while the  
27 long KER helix mediates DNA binding and stimulates *SpCAF-1* association with the polymerase  
28 accessory factor PCNA. By designing specific *SpCAF-1* mutants, we demonstrate that both histone and  
29 DNA binding are required for its functions *in vitro* and *in vivo*. We show that PCNA binding not only  
30 accelerates nucleosome assembly *in vitro* but is also essential for the proper targeting of the complex to  
31 the chromatin *in vivo*. Our structural and functional study reveals how the combination of disordered  
32 regions and folded modules in CAF-1 enable the dynamics of multiple interactions to promote histone  
33 deposition coupled to DNA synthesis.

34

## 1 **Introduction**

2           In eukaryotes, genomic DNA is packaged in a dynamic nucleoprotein complex, the chromatin,  
3 which protects DNA and regulates its accessibility. The fundamental repeat unit of chromatin, the  
4 nucleosome core particle, comprises 146 bp of DNA wrapped around a histone octamer including a  
5 tetramer of histone H3–H4 flanked by two dimers of H2A–H2B<sup>1</sup>. Histone chaperones are critical  
6 players in ensuring histone traffic and deposition. Without energy consumption, they escort histones,  
7 facilitate their transfer and deposition on DNA, and provide links with DNA based-processes such as  
8 DNA replication, repair and gene transcription<sup>2</sup>. In line with these key properties, perturbations of  
9 histone chaperones are associated with defects in genome and epigenome maintenance and function as  
10 found in cancer, aging and viral infections<sup>3-5</sup>. Discovered over thirty years ago<sup>6</sup>, conserved in all  
11 eukaryotes<sup>7</sup>, the histone chaperone Chromatin Assembly Factor 1 (CAF-1) is central and unique in  
12 promoting the deposition of replicative histones H3–H4 in a manner coupled to DNA synthesis, i.e.  
13 during DNA replication and repair, and is also involved in heterochromatin maintenance (see<sup>2,8</sup> for  
14 review). The unique feature of CAF-1 is that it provides a link with DNA synthesis via its association  
15 with the trimeric DNA polymerase processivity factor, Proliferation Cell Nuclear Antigen (PCNA),  
16 through PCNA Interacting Protein motifs (PIP)<sup>9-13</sup>.

17           CAF-1 comprises three subunits (**Figure 1a**)<sup>6,14,15</sup>. While progress in uncovering its  
18 molecular/genetic properties derives from work in *Saccharomyces cerevisiae*, and biochemical work in  
19 human cells, there is still a lack of atomic information. In *cerevisiae*, CAF-1 is a hetero-trimer that binds  
20 to a single H3–H4 dimer<sup>16,17</sup> and induces a conformational rearrangement promoting interaction with  
21 the DNA. Two complexes co-associate to ensure the deposition of H3–H4 tetramers on DNA in the first  
22 step for nucleosome assembly (see<sup>18</sup> for review). Two domains of the large subunit Cac1 contribute to  
23 DNA binding<sup>16,19</sup>, the conserved low complexity region called KER (for Lys, Glu and Arg rich) and the  
24 C-terminal Winged Helix Domain (WHD). These features are conserved in human CAF-1<sup>13</sup>. However,  
25 we still miss a complete view of the 3D organisation of the CAF-1 complex, and even most critically  
26 miss an understanding of whether its constitutive domains function in synergistic or independent manner  
27 to facilitate non only histone deposition but also contribute to a proper address in cells. Finally, the  
28 degree of conservation of these properties across species needs to be assessed.

29           To get further insights into CAF-1 function, we isolated the fission yeast complex (Pcf1-Pcf2-  
30 Pcf3) and investigated its binding mode with its three main partners, histones H3–H4, DNA and PCNA.  
31 Based on these structural insights, we designed targeted mutations to specifically alter Pcf1 interactions  
32 with DNA, PCNA and histones H3–H4. To probe their functions, we also analysed phenotypes of the  
33 corresponding mutants in fission yeast.

34  
35

## 1 Results

### 2 Global organization of the full-length *SpCAF-1* complex

3 The large subunit of CAF-1, present in all major groups of eukaryotes, exhibits significant  
4 sequence divergence (16% or 21% between *SpPcf1* and *ScCac1* or *HsCHAF1A/p150*, respectively).  
5 Given this high sequence divergence, conserved biochemical properties between *ScCAF-1* and *SpCAF-*  
6 *1* should reveal important functional features. From sequence alignments, the 6 main conserved regions  
7 previously proposed to contribute to the nucleosome assembly activity of CAF-1 can be inferred in  
8 *SpPcf1* sequence, a KER domain, a single PIP motif, an acidic domain (ED domain), the domains  
9 predicted to bind Pcf2 (2BD) and Pcf3 (3BD) and a C-terminal WHD domain (**Figure S1a**). Although  
10 *SpPcf1* is shorter than *ScCac1* and *HsCHAF1A/p150* (544 residues instead of 606 and 956, respectively)  
11 its sequence includes a remarkable high abundance of predicted Intrinsically Disordered Regions (IDRs)  
12 (**Figure 1b**). These IDRs include the predicted histone-binding domain (Pcf1\_ED), the PCNA (PIP  
13 motif) and the DNA binding domain (Pcf-1 KER).


14 We produced and purified the three subunits of *SpCAF-1* separately from bacteria and insect  
15 cells (**Figure 1c**, materials & methods). When isolated, both Pcf2 and Pcf3 are monomeric while Pcf1  
16 forms large soluble oligomers (**Figure S1b**). Mixing the subunits by pairs, we observed stable  
17 complexes for Pcf1-Pcf2 and Pcf1-Pcf3 by size exclusion chromatography (SEC). Pcf2 and Pcf3 did not  
18 interact with each other (**Figure S1b, S1c**) suggesting that the large subunit Pcf1 mediates the complex  
19 assembly. We next reconstituted and isolated the recombinant full-length (FL) *SpCAF-1* complex by  
20 SEC (**Figure 1c**). An experimental molecular weight of 179 kDa was calculated using Small Angle X-  
21 ray Scattering (SAXS), consistent with a 1:1:1 stoichiometry (**Figure S1d**). These data are in agreement  
22 with a globular complex with a significant flexibility (**Figure S1e**).

23 To determine the extent of disorder in the large subunit of *SpCAF-1*, Pcf1 was produced with  
24 uniform <sup>15</sup>N (or <sup>15</sup>N-<sup>13</sup>C) labeling. The CAF-1(<sup>15</sup>N-Pcf1) complex with unlabeled Pcf2 and Pcf3 was  
25 reconstituted and SEC-purified. Given the size of this complex (167 kDa), we expected that only amide  
26 signals from residues in long disordered regions could be observed by Nuclear Magnetic Resonance  
27 (NMR) spectroscopy. The <sup>15</sup>N-<sup>1</sup>H spectrum shows about 140 amide signals, revealing that up to a quarter  
28 of Pcf1 residues are intrinsically disordered in the full *SpCAF-1* complex (**Figure 1d**). These residues  
29 are located in four continuous segments of Pcf1 and define intrinsically disordered regions that we  
30 labeled IDR1 to IDR4 (**Figure 1b**). IDR1 corresponds to the ~50 N-terminal residues of the protein,  
31 IDR2 (181-198) is located between the PIP motif and the 3BD region, IDR3 (355-394) overlaps a large  
32 segment of the acidic ED domain and IDR4 (451-470) is located between the 2BD region and the C-  
33 terminal WHD domain. The boundaries of the four IDRs are in agreement with the segments of Pcf1  
34 predicted to harbor disorder with a high probability (**Figure 1b**).

35 We next build a model of the *SpCAF-1* complex using the AlphaFold2 multimer software (AF2)  
36 with one copy of each full-length protein (**Figure 1e, Figures S1f-l**). The model is consistent with our

1 biochemical data showing that Pcf1 mediates the complex assembly. Also, in agreement with their  
2 disordered nature, low values around 0.2-0.3 of the local quality of the model as calculated by the Local  
3 Distance Difference Test (pLDDT) were obtained in the four IDR segments with a remarkable match  
4 for the delimitations of the four IDR segments by pLDDT values and NMR data (**Figure 1b**).  
5 Accordingly, these segments are symbolized with a dashed line in **Figure 1e**. In contrast, significantly  
6 high pLDDT was obtained for the 3BD, 2BD and WHD domains of Pcf1 and for the two subunits Pcf2  
7 and Pcf3. (**Figure 1b, Figures S1f**). These data allowed to identify four independent modules, not  
8 predicted to interact with each other. The first module corresponds to the KER domain of Pcf1, predicted  
9 to form a long helix ending by the PIP motif. The second module contains the Pcf2 subunit, composed  
10 of 7 WD repeats arranged in a circular fold, and a segment of Pcf1 corresponding to the 2BD domain  
11 forming three short beta strands and a short helix (**Figure S1g-i**). In the third module, the 3BD domain  
12 of Pcf1 composed of 7 helices and 3 beta strands establishes a large interface with Pcf3, composed of 7  
13 circular WD repeats (**Figure S1j-l**). The fourth domain is the WHD domain. We next used these models  
14 to fit our SAXS data allowing flexibility between the four modules. The best model fitted the  
15 experimental data with a high accuracy and is in agreement with a relatively globular complex.  
16 Superimposing the generated models did not define a unique orientation between the four modules,  
17 suggesting that the complex has an inter-module flexibility (**Table S1, Figure S1m-n**).

18 Taken together, our findings indicate that the large subunit Pcf1 mediates the (1:1:1) complex  
19 assembly. Pcf1 includes four IDR, and can organize its key regions (KER, PIP, 3BD, ED, 2BD and  
20 WHD) allowing them to be exposed and bound by Pcf2 and Pcf3 simultaneously.




1

2 **Figure 1: The large *SpCAF-1* subunit includes four intrinsically disordered regions (IDR)** a Names for the  
3 large, the medium and the small subunits of CAF-1 in *H. sapiens*, *S. cerevisiae* and *S. pombe*. b Upper panel: The  
4 magenta line shows the predicted disorder of Pcf1 (spot disorder software) and the black line the  $\text{C}\alpha$  Local Distance  
5 Difference Test (pLDDT) calculated for Pcf1 residues by the AlphaFold2 model of the full *SpCAF-1* complex.  
6 Lower panel:  $\text{C}\alpha$  chemical shift index calculated for the 101 assigned residues. This  $\text{C}\alpha$  chemical shift index is  
7 consistent with their disordered nature. The four IDR regions are highlighted with pink semi-transparent vertical  
8 bars. The predicted domains of Pcf1 are labeled. c General strategy for the production of *SpCAF-1*. The lower  
9 panel shows the purification SEC profile and the SDS-PAGE purity of the sample. d  $^1\text{H}$ - $^{15}\text{N}$  SOFAST-HMQC  
10 spectrum of the FL *SpCAF-1* complex composed of uniformly labeled  $^{15}\text{N}$ -Pcf1 and unlabeled Pcf2 and Pcf3  
11 (*SpCAF-1*( $^{15}\text{N}$ -Pcf1)). The assigned signals are labeled. e AF2 model of the *SpCAF-1* complex. The four IDR  
12 segments are shown with a dashed line. The relative orientation of the four modules is arbitrary.

1 **In the FL *SpCAF-1* complex, the acidic ED domain is disordered but folds upon histone binding**

2 We next investigated the interaction of *SpCAF-1* with histones H3–H4. A stable complex was  
3 isolated by SEC at low (150 mM NaCl) and high (1 M NaCl) salt concentrations, confirming that the  
4 reconstituted *SpCAF-1* complex tightly binds histones (**Figure 2a**). SAXS measurements at low salt  
5 allowed to calculate an experimental molecular weight of 193 kDa for this complex, showing that  
6 *SpCAF-1* binds a dimer of histones H3–H4 (**Figure S1d**). In addition, these data are compatible with a  
7 more extended shape compared to *SpCAF-1* alone (**Figure S1e**).

8 Addition of histones to *SpCAF-1*(<sup>15</sup>N-Pcf1) led to a drastic decrease in intensity of the NMR  
9 signal specifically for residues in the IDR3 segment (**Figure 2b, Figure S2a**). To further characterize  
10 this domain, we designed a short construct of Pcf1 (325-396), called Pcf1\_ED, corresponding to the  
11 IDR3 segment extended in its N-terminus with the conserved acidic segment (325-355) (**Figure 2c,**  
12 **Figure S1a**). We confirmed the fully disordered nature of Pcf1\_ED by NMR (**Figure S2b-c**). Signals  
13 corresponding to residues 355-394 (IDR3) remarkably overlap in the spectra of Pcf1\_ED and *SpCAF-*  
14 *1*(<sup>15</sup>N-Pcf1) (**Figure S2a**), showing that this segment was fully flexible in *SpCAF-1*, and did not interact  
15 with other regions of the complex. Upon binding of unlabeled histones H3–H4, we observed the  
16 vanishing of almost all NMR signals of <sup>15</sup>N Pcf1\_ED as in the full *SpCAF-1* complex (**Figure 2d**). In  
17 contrast, a large part of signals (338-396) did not vanish anymore upon addition of a histone complex  
18 preformed with two other histone chaperones known to compete with CAF-1 for histone binding<sup>16</sup>,  
19 Asf1–H3–H4–Mcm2(69-138) (**Figure 2d**). This region of the ED domain, is indeed in direct  
20 competition with Asf1 and Mcm2 whose histone binding modes are well established (**Figure 2e**)<sup>20,21</sup>.  
21 Fully consistent with this NMR competition experiment, this segment of Pcf1\_ED domain was predicted  
22 by AlphaFold2 to interact with histones H3–H4 through the same surface as the one bound by Mcm2  
23 (**Figure 2f, Figure S2d**). Two highly conserved positions in Pcf1, L359 and F380, are thus proposed to  
24 mediate histone H3–H4 binding in the same region as Mcm2 (**Figure 2f**). We next used these  
25 AlphaFold2 models to fit the SAXS curve of the *SpCAF-1*–H3–H4 complex allowing reorientation of  
26 the different modules (**Figure S10-p**). Remarkably, all generated models show a significant exclusion  
27 of the KER domain from the complex, suggesting that the KER domain of *SpCAF-1* becomes more  
28 accessible upon histone binding.



1

Figure 2: The acidic ED domain binds histones alone and in the full CAF-1 complex

2 **Figure 2: The acidic ED domain binds histones alone and in the full *SpCAF-1* complex**  
3 and the SDS-PAGE purity of *SpCAF-1*-H3-H4 histones at 150 mM NaCl and 1 M NaCl. **b** Mapping of the  
4 interaction between *SpCAF-1* (<sup>15</sup>N-Pcf1) and *SpH3*-H4 histones, using the intensities ratio (I/I0), where I and I0  
5 are the intensity of the signals <sup>1</sup>H-<sup>15</sup>N SOFAST-HMQC spectra before and after addition of histones, respectively.  
6 **c** Sequence Logo of the ED domain generated with a large data set of Pcf1 homologues. The position of the two  
7 conserved residues Y340 and W348, mutated in ED\* are indicated with stars and conserved Pcf1 L359 and F380  
8 residues with five and four branch stars respectively. **d** Mapping of the interaction between Pcf1\_ED or Pcf1\_ED\*  
9 with *SpH3*-H4 histones using the intensities ratio (I/I0) as in b. Histones were added alone or previously  
10 complexed with histones chaperones. **e** Cartoon representation of the complex between human histones H3-H4  
11 (light blue and cyan), Asf1 (light grey) and Mcm2 (dark grey) (PDB: 5BNX). **f** AlphaFold2 model of Pcf1 (353-  
12 385) (as red cartoon), corresponding to the segment of the ED domain indicated in red, in complex with histones  
13 H3-H4 (light blue and cyan surface) superimposed with Mcm2 and Asf1 as in panel e. The two insets represent  
14 zoomed views of the sidechains of the conserved Pcf1 L359 and F380 residues (red sticks) binding into H4 and  
15 H3 pockets, respectively. The same four and five branch stars are used to label these positions in the logo panel c.

1 The NMR competition experiment also reveals that an additional region of Pcf1\_ED domain  
2 (338-351) is involved in the interaction with H3–H4 but is not competing with the Asf1-Mcm2 module.  
3 (**Figure 2d**). In order to alter the interaction of the ED domain with histones without modifying its  
4 charge and without interfering with Asf1 or Mcm2 binding, we identified from sequence alignments in  
5 this segment (**Figure 2c**), two invariant hydrophobic residues, Y340 and W348, that were mutated into  
6 alanines (mutant called ED\*, **Figure S1a**). As expected, the isolated Pcf1\_ED\* domain showed almost  
7 no histone binding as observed by the intensity of  $^1\text{H}$ - $^{15}\text{N}$  NMR signals (**Figure 2d**). We next monitored  
8 the impact of the ED\* mutations in the context of the full *SpCAF-1* complex. To do so, the mutations  
9 Y340A-W348A were introduced in the full length Pcf1, and the complex reconstituted with the  
10 uniformly  $^{15}\text{N}$  labeled Pcf1(ED\*) and unlabeled Pcf2 and Pcf3 (**Figure S2e**). The  $^1\text{H}$ - $^{15}\text{N}$  NMR spectrum  
11 of this mutant was similar that of the WT complex, but upon addition of unlabeled histones H3–H4 no  
12 major change was observed (**Figure S2a**), which strongly suggest an alteration of the histone binding  
13 of this mutant.

14 In summary, we identified critical amino-acids in the ED domain involved in H3–H4 binding.  
15 We also showed that addition of histones leads to a conformational change in the *SpCAF-1* complex  
16 with less disorder in the ED domain and an increased accessibility of the KER domain.

17

## 18 ***SpCAF-1* binds dsDNA longer than 40bp**

19 We next analyzed the DNA binding properties of *SpCAF-1*. Electrophoretic mobility shift  
20 assays (EMSA) were performed with a DNA ladder as substrate in order to determine the minimal DNA  
21 size for *SpCAF-1* binding. The complex *SpCAF-1* showed significant binding for DNAs longer than  
22 40bp (**Figure S3a**). EMSAs with a double-stranded 40bp DNA fragment confirmed the homogeneity of  
23 the bound complex. When increasing the *SpCAF-1* concentration, additional mobility shifts suggest, a  
24 cooperative DNA binding (**Figure 3a**). Micro-Scale Thermophoresis (MST) measurements were next  
25 performed using an alexa-488 labeled 40bp dsDNA (**Figure 3b, Table 1**). The curves were fitted with  
26 a Hill model with a  $\text{EC}_{50}$  value of  $0.7 \pm 0.1 \mu\text{M}$  and a cooperativity (Hill coefficient,  $h$ ) of  $2.7 \pm 0.2$ , in  
27 line with a cooperative DNA binding of *SpCAF-1*.

28 **Table 1: Experimental affinities of different *SpCAF-1* constructs with a 40bp dsDNA measured by**  
29 **Microscale thermophoresis (MST).**


Construct	EC50 ( $\mu\text{M}$ )	Hill coeff., $h$
Pcf1_KER	$1.1 \pm 0.2$	$3.3 \pm 0.5$
Pcf1_KER*	$12.2 \pm 0.7$	$1.5 \pm 0.3$
Pcf1_KER-PIP	$1.9 \pm 0.3$	$5.2 \pm 0.9$
Pcf1_WHD	Not detected	Not detected
<i>SpCAF-1</i> WT	$0.7 \pm 0.1$	$2.7 \pm 0.2$
<i>SpCAF-1</i> ( $\Delta\text{WHD}$ )	$0.7 \pm 0.1$	$2.3 \pm 0.3$
<i>SpCAF-1</i> (KER*)	$2.8 \pm 0.4$	$1.3 \pm 0.3$
<i>SpCAF-1</i> (ED*)	$1.0 \pm 0.1$	$2.3 \pm 0.1$
<i>SpCAF-1</i> (PIP*)	$0.7 \pm 0.1$	$2.7 \pm 0.3$



## 1 **The KER domain is the main DNA binding region of *Sp*CAF-1**

2           The KER and WHD domains of the CAF-1 large subunit were shown to be involved in DNA  
3 binding in *Sc*CAF-1 and *Hs*CAF-1<sup>13,16,19,22</sup>. We were thus interested to explore the conservation of these  
4 features in Pcf1. We first isolated the KER domain (Pcf1\_KER, **Figure S1a**), and an extended fragment  
5 we called Pcf1\_KER-PIP (**Figure S1a**), which includes the PIP motif (Q<sub>172</sub>-L-K-L<sub>175</sub>-N-N-F<sub>178</sub>-F<sub>179</sub>).  
6 These domains are predicted by AlphaFold2 to form a long helix with partial disorder at both ends and  
7 possible extension over the first half of the PIP motif (**Figure 1d, Figure 3c**). Using a combination of  
8 circular dichroism (CD) (**Figure S3b-c**), SEC-SAXS (**Figure S1d-e, Figure S3d**) and NMR (**Figure**  
9 **S3e-f**), we confirmed that the isolated KER domain of Pcf1 domain forms a straight monomeric helix,  
10 partially continuing over the PIP motif. This long helix exhibits a strong bias in amino acid composition  
11 and remarkably, almost all basic residues are positioned on the same side of the helix (**Figure 3d**)  
12 providing a suitable interface for DNA binding<sup>13</sup>. We performed EMSA using a DNA ladder as substrate  
13 and we found that Pcf1\_KER domain binds DNA that are longer than 40bp, as observed with the full  
14 *Sp*CAF-1 complex (**Figure S3e**). EMSAs with double strand 40bp DNA fragment showed the presence  
15 of multiple bands for Pcf1\_KER bound DNA, indicating a possible cooperative DNA binding of this  
16 fragment (**Figure 3d**). Affinity measurements by MST led to a EC<sub>50</sub> of  $1.1 \pm 0.2 \mu\text{M}$  for Pcf1\_KER  
17 with a cooperativity around 3, consistent with EMSA experiments (**Figure 3d, Table 1**). The DNA  
18 binding properties of Pcf1\_KER-PIP are comparable to that of Pcf1\_KER (**Figure 3e, Table 1, Figure**  
19 **S3f**). The EC<sub>50</sub> obtained for the isolated Pcf1\_KER are also close that of the full *Sp*CAF-1 complex  
20 ( $0.7 \pm 0.1 \mu\text{M}$ ) suggesting that the KER domain constitutes the principal DNA binding domain of  
21 *Sp*CAF-1.

22           Based on these results, we designed a mutant called Pcf1\_KER\* with a charge inversion for five  
23 positive residues at the C-terminus of the potential DNA binding face of the KER helix (R147E-K150E-  
24 K154E-R161E-K168E) (**Figure 3c, Figure S1a**). The CD analysis of Pcf1\_KER\* shows this mutant is  
25 mainly helical (**Figure S3g**). MST quantification confirmed that the mutation of Pcf1\_KER\* impaired  
26 DNA binding by a factor of 10 even-though residual DNA binding remained (**Figure 3e, Figure S3h-j,**  
27 **Table 1**). The KER\* mutation was then introduced in the full complex *Sp*CAF-1(KER\*) (**Figure S1a,**  
28 **Figure S2e**) and we confirmed by MST and EMSA its lower affinity for dsDNA (**Figure 3b, Figure**  
29 **S3k, Table 1**). Importantly, the NMR signals of all IDR for this mutant with or without histones were  
30 close to that of the WT (**Figure S3l-m**) indicating that the KER\* mutation did not impair histone  
31 binding.



1

2

3

4

5

6

7

8

9

10

11

12

13

**Figure 3: Pcf1\_KER is the main DNA binding domain of SpCAF-1:** **a** EMSA with SpCAF-1 and 40 dsDNA ( $1\mu\text{M}$ ) revealed with SYBR SAFE staining. **b** Microscale thermophoresis (MST) fitted curves of SpCAF-1 WT and mutants with 40bp dsDNA. **c** Upper panel: Modelled structure of the Pcf1\_KER-PIP domain (56-185) rainbow coloured according to the pLDDT of each residue. Red corresponds to pLDDT values of 1 and dark blue of 0. Middle panel same model represented with its electrostatic surface. Lower panel: zoom of the C-terminus of the KER domain and the PIP motif. The five mutated residues are labeled and highlighted with spheres. **d** EMSA of Pcf1\_KER binding with a 40bp dsDNA ( $1\mu\text{M}$ ) revealed with SYBR SAFE staining **e** MST fitted curves of Pcf1\_KER constructs and mutants with 40bp dsDNA. **f** Overlay of the calculated model of the WHD domain obtained with the CS-rosetta software (light orange) using NMR assignments of the domain (**Figure S3n**), with AlphaFold2 (gold) and the structure of Cac1 WHD from budding yeast (PDB 5jbm, in grey)<sup>23</sup>(Grey). **g** EMSA revealed with SYBR SAFE staining of Pcf1\_WHD domain with a 40 dsDNA ( $1\mu\text{M}$ ).

## 1 **The C-terminal of Pcf1 folds as a WHD domain but does not bind DNA**

2 We next isolated the Pcf1\_WHD domain (**Figure S1a**) and confirmed by NMR and AlphaFold2  
3 that its global fold is similar to *Sc*WHD<sup>19,23</sup> (**Figure 3f, Figure S3n**). Unexpectedly, Pcf1\_WHD does  
4 not interact with DNA of any size (**Figure 3g, Figure S3n**). The residues involved in DNA binding in  
5 *Sc*WHD, K564 and K568, correspond to S514 and G518 in *Sp*WHD, respectively, leading to a different  
6 electrostatic surface, probably not favorable for DNA binding (**Figure S3p-q**). To further investigate  
7 the role of the WHD domain of *Sp*CAF-1, the WHD domain was deleted in the reconstituted *Sp*CAF-  
8 1( $\Delta$ WHD) complex (**Figure S1a Figure S2e**) and analyzed by EMSA and NMR. We observed the  
9 similar DNA binding property and IDR properties for *Sp*CAF-1( $\Delta$ WHD) and the WT complex (**Table**  
10 **1, Figure 3b, Figure S3k-m**).

11 Together our results show that the KER domain constitutes the main DNA binding region of  
12 *Sp*CAF-1 and that the WHD domain does not contribute to this binding.

13


## 14 **Crosstalk between DNA and PCNA binding**

15 The PIP motif of Pcf1 was found crucial for *Sp*CAF-1 interaction with PCNA *in vivo*<sup>12</sup>. Given  
16 its proximity with the KER domain, we further investigated potential cross-talks between PCNA and  
17 DNA binding. We first measured by isothermal microcalorimetry (ITC) an affinity of  $7.1 \pm 1.3 \mu\text{M}$   
18 between *Sp*PCNA and a short PIP motif segment (**Figure S4a, Table 2**). This affinity is in the same  
19 range (2-fold less affine) as a peptide isolated from the replicative polymerase delta from *S. pombe*  
20 Cdc27 (**Figure S4a, Table 2**). In agreement with its consensus sequence, the binding mode of Pcf1\_PIP  
21 motif to *Sp*PCNA is predicted by AlphaFold to be canonical (**Figure S4b**). Consistently, no binding was  
22 observed for the Pcf1\_PIP\* peptide with 4 Alanine mutations, previously designed to disrupt the PIP  
23 motif (**Figure S4a, Table 2**)<sup>12</sup>. We next measured the affinity of the longer fragment Pcf1\_KER-PIP for  
24 *Sp*PCNA and observed an affinity gain of a factor 10 ( $0.7 \pm 1.3 \mu\text{M}$ ) (**Figure S4c, Table 2**), revealing  
25 interactions between the KER domain and PCNA. ITC also fits a stoichiometry of  $\sim 2$  Pcf1\_KER-PIP  
26 per PCNA trimer, suggesting that, in each PCNA trimer, one monomer remains unbound and potentially  
27 accessible for binding to other partners. Pcf1\_KER-PIP\* did not interact with PCNA confirming the  
28 importance of the PIP motif for this association (**Figure S4c, Table 2**). The KER\* mutation impaired  
29 the interaction of Pcf1\_KER\*-PIP with PCNA of a factor 10 reaching the affinity of the short isolated  
30 Pcf1 PIP peptide (**Figure S4c, Table 2**). Collectively these results show that both the PIP motif and the  
31 C-terminal part of the KER domain are involved in PCNA binding.

32 To reveal possible crosstalk between CAF-1 binding to PCNA and DNA, we analysed, in the  
33 presence or absence of dsDNA, the binding of the full *Sp*CAF-1 complexes (WT *Sp*CAF-1, *Sp*CAF-  
34 1(PIP\*), *Sp*CAF-1(ED\*), *Sp*CAF-1(KER\*) and *Sp*CAF-1( $\Delta$ WHD)) with recombinant *Sp*PCNA, using  
35 EMSA (**Figure 4a, Figure S4d**). For all combinations tested, we quantified binding by monitoring the

1 disappearance of free PCNA (**Figure 4b**) and free DNA (**Figure 4c**). In this assay, only 20% of free  
 2 PCNA intensity was lost by addition of DNA (**Figure 4b**), probably because the PCNA trimer can slide  
 3 along the linear DNA and dissociates during the migration. In the absence of DNA, we observe a small  
 4 but significant decrease of free PCNA upon addition of WT *SpCAF-1*, in agreement with the relatively  
 5 low binding affinity between Pcf1\_KER helix and PCNA (**Table 2**). In contrast, in the presence of  
 6 dsDNA, addition of an excess of WT *SpCAF-1* leads to the complete disappearing of the free PCNA  
 7 band and to a large shift of the band corresponding to *SpCAF-1*-DNA, corresponding to a larger complex  
 8 engaging CAF-1, PCNA and DNA (**Figure 4a**). *SpCAF-1*(ED)\* and *SpCAF-1*( $\Delta$ WHD) show similar  
 9 binding properties for PCNA and DNA compared to WT CAF-1. In contrast, *SpCAF-1*(PIP\*) binds  
 10 DNA like the WT, but is strongly impaired for PCNA binding alone and in the presence of DNA, while  
 11 *SpCAF-1*(KER\*) is impaired for binding both DNA and *SpPCNA*. In agreement, the large shifted band  
 12 corresponding to a *SpCAF-1*-PCNA-DNA complex is not observed for these two mutants (**Figure**  
 13 **S4d**).

14 Altogether, our data show the stabilization of the CAF-1-PCNA interaction by DNA that  
 15 requires both the KER domain and the PIP motif but not the ED and WHD domain. Conversely, the  
 16 capacity of CAF-1 to bind PCNA does not impair its interaction with DNA.



17  
 18 **Figure 4: The *SpCAF-1*(KER\*) mutant is affected for PCNA binding.** **a** EMSA showing interactions of  
 19 purified *SpCAF-1* (at the indicated concentrations), with or without recombinant *SpPCNA* (3μM) in the presence  
 20 and absence of 40bp dsDNA (1μM), revealed with Coomassie blue (upper panel) and with SYBR SAFE staining  
 21 (lower panel). **b** Quantification of bound *SpPCNA* in the EMSA shown in panel **a** and in **Figure S4d** for *SpCAF-1*  
 22 and mutants. Values are indicated in % compared to the free PCNA reference (PCNA alone in line 1 in panel **a**)  
 23 after addition of *SpCAF-1* (WT or mutant) at the indicated concentration and in the presence (filled bars) or absence  
 24 (dashed bars) of 40bp dsDNA (1μM). **c** Quantification of bound DNA for EMSA shown in panel **a** and in **Figure**  
 25 **S4d** for *SpCAF-1* and mutants. Bound DNA in % is compared to the free DNA reference (line 5 in panel **a**)  
 26 after addition of *SpCAF-1* (WT or mutant) at the indicated concentration and in the presence (filled bars) or absence  
 27 (dashed bars) of *SpPCNA* (3μM). All experiments were done in duplicates. Mean values are indicated and error  
 28 bars shows their standard deviation.

1 **Table 2: Interactions parameter with *Sp*PCNA measured by isothermal microcalorimetry (ITC):** \*The  
 2 stoichiometry (N) is calculate as a molar ratio of monomeric PCNA.

3

Ligand	Kd ( $\mu$ M)	$\Delta$ G (kCal.M <sup>-1</sup> )	N*	$\Delta$ H (kCal.M <sup>-1</sup> )	-T $\Delta$ S (kCal.M <sup>-1</sup> )
Pcf1_PIP	7.1 $\pm$ 1.3	-6.9 $\pm$ 0.1	0.97 $\pm$ 0.08	-2.9 $\pm$ 0.2	-0.39 $\pm$ 0.3
Pcf1_PIP*	undetectable	ND	ND	ND	ND
Pcf1_KER-PIP	0.7 $\pm$ 0.2	-8.2 $\pm$ 0.2	0.64 $\pm$ 0.04	+2.9 $\pm$ 0.6	-11.2 $\pm$ 0.8
Pcf1_KER*-PIP	7.1 $\pm$ 1.5	-6.9 $\pm$ 1.2	0.7 $\pm$ 0.2	+1.0 $\pm$ 0.5	-7.9 $\pm$ 0.7
Pcf1_KER*-PIP*	undetectable	ND	ND	ND	ND
Cdc27_PIP	3.5 $\pm$ 0.3	-7.3 $\pm$ 0.1	0.9 $\pm$ 0.1	-4.8 $\pm$ 0.02	-2.4 $\pm$ 0.1


4

5 ***In vitro* histone deposition properties of *Sp*CAF-1 mutants**

6 We next examined the ability of the full *Sp*CAF-1 complex reconstituted with the four Pcf1  
 7 mutants (*Sp*CAF-1(PIP\*), *Sp*CAF-1(ED\*), *Sp*CAF-1(KER\*), *Sp*CAF-1( $\Delta$ WHD)) to promote  
 8 nucleosome assembly mediated by CAF-1 in a complex environment closer to physiological conditions.  
 9 We used *Xenopus* high speed egg extract (HSE) that are powerful systems competent for chromatin  
 10 assembly and effective to exploit depletion/complementation assays<sup>24</sup>. We depleted HSE for the  
 11 endogenous *Xenopus* CAF-1 largest subunit (xp150) and assessed the capacity of *Sp*CAF-1(PIP\*),  
 12 *Sp*CAF-1(ED\*), *Sp*CAF-1(KER\*) and *Sp*CAF-1( $\Delta$ WHD) to complement these xp150-depleted  
 13 extracts<sup>16,24</sup> (**Figure S5**). We monitored nucleosome assembly coupled to DNA synthesis using as a  
 14 template a circular UV-damaged plasmid enabling to analyse by supercoiling assay and nucleotide  
 15 incorporation simultaneously both repair synthesis and nucleosome formation (**Figure 5**)<sup>10</sup>. We verified  
 16 that p150-depleted HSE lacked the capacity to promote nucleosome assembly on labeled DNA when  
 17 compared to mock depleted HSE, and that the recombinant WT *Sp*CAF-1 complex efficiently rescued  
 18 the loss of xp150 as attested by the detection of supercoiled form I. In contrast, when we complemented  
 19 the depleted extract with *Sp*CAF-1 mutant complexes *Sp*CAF-1(ED\*), *Sp*CAF-1(KER\*), *Sp*CAF-  
 20 1( $\Delta$ WHD) we did not detect the supercoiled form I. This indicates that these mutants cannot promote  
 21 nucleosome assembly (**Figure 5**). When we used the *Sp*CAF-1(PIP\*) mutant, we did not detect  
 22 supercoiling on labeled DNA at 45 minutes, yet at 2 hours supercoiling ultimately reached levels  
 23 achieved using the WT *Sp*CAF-1 (**Figure 5**, bottom, synthesized DNA). Interestingly both for 45 and 2  
 24 hours of assembly *Sp*CAF-1(PIP\*) mutant yielded more supercoiling than any of the *Sp*CAF-1(ED\*),  
 25 *Sp*CAF-1(KER\*), *Sp*CAF-1( $\Delta$ WHD) mutants. Thus, while mutation in the PIP motif of Pcf1 impaired  
 26 chromatin assembly at a short time, when more time is given, it allows ultimately to catch up with the  
 27 wild type. In contrast, none of the *Sp*CAF-1(ED\*), *Sp*CAF-1(KER\*), *Sp*CAF-1( $\Delta$ WHD) mutants could  
 28 catch up, leading to a *Sp*CAF-1 complex deficient for nucleosome assembly even after longer incubation  
 29 time. Therefore, these data validate the important role of the amino-acids Y340 and W348 within the  
 30 ED domain in Pcf1 and the importance to preserve the integrity of the KER and WHD domain to ensure  
 31 a proper *Sp*CAF-1 mediated nucleosome assembly on synthesized DNA.

1 Together, these results indicate that the PIP domain provides Pcf1 with the ability to accelerate  
2 nucleosome assembly, yet the integrity of the ED, KER and WD domain proved absolutely mandatory  
3 for an efficient *SpCAF-1* mediated nucleosome assembly.

4



5

6 **Figure 5: Rescue using Y340 and W348 in the ED domain, the intact KER DNA binding domain and the C-**  
7 **terminal WHD of Pcf1 in *SpCAF-1* mediated nucleosome assembly.** Supercoiling analysis after 45 (left) and  
8 120 (right) minutes incubation to monitor chromatin assembly in control mock and xenopus p150-depleted HSE.  
9 Total DNA visualized by EtBr staining (top) and synthesized DNA visualized by biotin detection (bottom) are  
10 shown. The xenopus p150-depleted HSE is either mock complemented (-) or complemented using *SpCAF-1*  
11 complex composed of wild type Pcf1(WT) or mutants Pcf1(PIP\*), Pcf1\_ED\*, Pcf1(KER\*), or Pcf1(ΔWHD) as  
12 indicated. T: pBS plasmid incubated without extract run in parallel serves as a migration control to locate  
13 supercoiled DNA. The position of relaxed (II) and supercoiled (I) DNA are indicated.


14

#### 15 **Association of *SpCAF-1* with histones impacts PCNA interaction *in vivo***

16 We next investigated the consequences of the four Pcf1 mutations previously characterized *in*  
17 *vitro*, on *SpCAF-1* function *in vivo* by introducing the respective mutations at the endogenous *pcf1* gene.  
18 Both WT and mutants were FLAG tagged in their N-terminal part. Immuno-blot of total cell extract with  
19 anti-flag antibody showed that all mutated forms of Pcf1 were expressed to the same level than WT Pcf1  
20 (**Figure S6a**).

21 We first tested PCNA–Pcf1 interaction by co-immunoprecipitation of FLAG-Pcf1 and found  
22 that Pcf1(ΔWHD) showed a similar PCNA interaction than WT Pcf1 (**Figure 6a-b** and **Figure S6b**). No  
23 interactions were detected with Pcf1(PIP\*) and Pcf1(KER\*), in line with the requirement of the KER  
24 and PIP domains for PCNA binding (**Figure 4, Table 2**). Surprisingly, we found that Pcf1(ED\*) binds  
25 eight times more to PCNA than the WT Pcf1 (**Figure 6a-b**) although the corresponding *SpCAF-1*(ED\*)  
26 bound PCNA with or without DNA *in vitro*, similarly to WT (**Figure 4, Figure S4d**). This suggest an  
27 interplay *in vivo* between the binding of CAF-1 to PCNA and its capacity to bind histones.

28



1

2 **Figure 6: Association of CAF-1 with histone is coupled to PCNA interaction *in vivo*.** **a** Anti-FLAG Pulldown  
 3 to address PCNA–CAF-1 interaction *in vivo* in indicated strains. **b** Quantification of bound PCNA from (a). **c**  
 4 Example of Pcf2-GFP foci in living cells in indicated strains, according to cell morphology. **d** Quantification of  
 5 cells showing Pcf2-GFP foci, according to cell morphology in indicated strains. Values are means of at least 3  
 6 independent experiments ± standard error. At least 1000 nuclei were analysed per strain. P values are indicated  
 7 with stars and were calculated using the student test.

1 To probe this further, we analyzed *SpCAF-1* foci that were reported to colocalize with PCNA  
2 during DNA replication<sup>12</sup>. Since previously reported GFP-tagged forms of Pcf1 are not fully functional,  
3 we made use of cells expressing Pcf2-GFP, a functional tagged form<sup>25</sup>. As expected, Pcf2-GFP formed  
4 discrete foci during the bulk of S-phase (septated cells) until late S/early G2 phase (late cytokinesis  
5 cells) but not during G2 phase (mono-nucleated cells) in a Pcf1-dependent manner (**Figure 6c-d**). The  
6 *pcf1( $\Delta$ WHD)* mutation behaved like the *WT* in this assay. In contrast, S-phase Pcf2 foci were  
7 undetectable when Pcf1–PCNA interaction is impaired (in *pcf1(KER\*)* and *pcf1(PIP\*)*). Interestingly,  
8 Pcf2-GFP foci were more frequent in all cell cycle phases in *pcf1(ED\*)* mutated cells compared to *WT*.  
9 Simultaneous acquisition of GFP fluorescence in living *WT* and mutated *pcf1* cells revealed that Pcf2-  
10 GFP foci were more abundant and brighter in *pcf1(ED\*)* cells compared to *WT* (**Figure S6c**), suggesting  
11 a higher concentration of CAF-1 within replication factories. In conclusion, the ability of CAF-1 to  
12 localize to replication factories correlates with its association with PCNA *in vivo*, possibly modulated  
13 by the histone binding.

14


#### 15 **The WHD domain specifies CAF-1 function in distinct cellular processes.**

16 In *S. pombe*, CAF-1 is involved in the replication-coupled maintenance of heterochromatin<sup>15</sup>.  
17 We employed a strain in which *ura4<sup>+</sup>* is inserted at the peri-centromeric heterochromatin of the  
18 chromosome I (**Figure 7a**, top panel). The expression of *ura4* is repressed by the surrounding  
19 heterochromatin resulting in a poor growth on uracil-depleted media and resistance to 5-fluoro-orotic  
20 acid (5FOA) (**Figure 7a**, bottom panel). As previously reported, the deletion of *pcf1* resulted in a better  
21 cell growth on uracil-depleted media compared to *WT* cells, showing that the heterochromatin is not  
22 properly maintained, leading to the derepression of *ura4<sup>+</sup>*. All mutants, excepted *pcf1( $\Delta$ WHD)*, exhibited  
23 defects in *ura4* silencing, similar to the one observed in the null mutant. This shows that the inability to  
24 interact with histone, PCNA and DNA results in a complete lack of CAF-1 function in maintaining  
25 heterochromatin. Interestingly, the WHD domain, while required for chromatin assembly *in vitro*  
26 (**Figure 5**), is dispensable for the maintenance of heterochromatin. We thus investigated further the role  
27 of this domain.

28 We analyzed the accumulation of Rad52-GFP foci as a readout of global accumulation of DNA  
29 damage (**Figure 7b**). The deletion of *pcf1* led to a modest but significant increase in the frequency of  
30 cells showing Rad52-GFP foci. A similar effect was observed in *pcf1(ED\*)* mutated cells, while the  
31 presence of a CAF-1 complex unable to interact with PCNA resulted in a greater increase (in *pcf1(PIP\*)*  
32 and *pcf1(KER\*)* mutants). In contrast, no significant increase was observed in *pcf1( $\Delta$ WHD)* cells. Thus,  
33 both CAF-1 interaction with histone and PCNA prevent the accumulation of DNA damage, but histone  
34 deposition is not absolutely required.



1 The deletion of *pcf1* is synthetic lethal with the deletion of *hip1*, the gene encoding one subunit  
 2 of the fission yeast HIRA complex<sup>25</sup>, indicating that in the absence of replication-coupled histone  
 3 deposition by CAF-1, cell viability relies on H3–H4 deposition by HIRA as suggested in human<sup>26</sup>. We  
 4 found that *pcf1(KER\*)*, *pcf1(ΔWHD)* or *pcf1(PIP\*)* are co-lethal with *hip1* deletion (**Figure 6d**). Cells  
 5 harboring *pcf1(ED\*)* were viable when combined with *hip1* deletion, but exhibited a severe growth  
 6 defect (**Figure 6a**), suggesting that CAF1(ED\*) complexes can still perform some histone deposition *in*  
 7 *vivo*. These genetic interactions indicate that binding of CAF-1 to PCNA, DNA and histones are critical  
 8 determinants for its function *in vivo*, as well as the WHD C-terminal domain.



9

10 **Figure 7 : The WHD domain of SpCAF-1 specifies CAF-1 function.** **a** Top: Schematic representation  
 11 of the silencing assay used. Otr: outer repeats, imr; inner repeats: cnt1; central core of the centromere 1. Bottom:  
 12 Serial fivefold dilution on indicated strains on indicated media. **b** Example of Rad52-GFP foci in *WT* cells. **c**  
 13 Quantification of Rad52-GFP foci in indicated strains. Values are means of at least 3 independent experiments ±  
 14 standard error of the mean. P values are indicated as stars and were calculated with the student test. At least 1000  
 15 nuclei were analyzed per strain. **d**. Co-lethality assay. Tetrad dissections of cells deleted for *hip1* (*hip1Δ*) crossed  
 16 with cells deleted for *pcf1* (*pcf1Δ*) (grey) or harbouring *pcf1(PIP\*)* (magenta), *pcf1(ED\*)* (red), *pcf1(KER\*)*  
 17 (purple) or *pcf1(ΔWHD\*)* (orange). Spores with double mutations are surrounded.

## 1 Discussion

2 In the present work, we provide a comprehensive study of the histone chaperone CAF-1 from  
3 *S. pombe*. Despite the low sequence conservation between orthologues of the large subunit of CAF-1,  
4 Pcf1 from *SpCAF-1* mediates the heterotrimer complex that binds dimeric histones H3–H4, as does  
5 *ScCAF-1*<sup>16,27,28</sup>. Using AlphaFold2, we built a structural model of the *SpCAF-1*, fully compatible with  
6 all our experimental data (**Figure 1**). This structure defines the 2BD and 3BD regions in Pcf1 as involved  
7 in the binding of Pcf2 and Pcf3, respectively. This matches remarkably the corresponding segments  
8 identified by HDX in *ScCAF-1*<sup>28</sup>. In line with previous observations in *HsCAF-1*<sup>29</sup> and *ScCAF-1*<sup>17,23,28</sup>,  
9 the ED domain of *SpCAF-1* is crucial for histone binding. (**Figure 2**). Mainly disordered in the free  
10 chaperone, we show that this domain folds upon histone binding, promoting a conformational change  
11 with increased accessibility of the KER domain (**Figure S1**). *SpCAF-1* binds dsDNA longer than 40bp  
12 in the micromolar affinity range (**Figure 3, Table 1, Figure S3**) through the KER domain forming a  
13 long monomeric helix with a positively charged face. Interestingly, the helix length roughly corresponds  
14 to the size of 40bp dsDNA, suggesting that it could lie on DNA and act as a DNA ruler to sense free  
15 DNA for histone deposition<sup>13,16,30</sup>. Together, our findings highlight the conservation of CAF-1 properties  
16 in histone deposition mechanism *in vitro*, and thus unifies the current model<sup>18</sup>.

17 This work revealed strong interdependency between histone deposition by CAF-1 and its  
18 association with PCNA. The PIP\* mutation did not compromise DNA binding of *SpCAF-1 in vitro*  
19 (**Figure S4**). Conversely, upon interaction with DNA, *SpCAF-1* interacted tighter with PCNA (**Figure**  
20 **4**), consistently with a recent study in budding yeast<sup>31</sup>. We show that *SpCAF-1(PIP\*)* is still able to  
21 assemble histones *in vitro*, although slower than WT-*SpCAF-1*. In contrast, *in vivo*, *pcf1(PIP\*)*  
22 phenocopy the deletion of *pcf1*. From these results, we conclude that the binding of *SpCAF-1* to PCNA  
23 though the PIP motif is required for *SpCAF-1* functions *in vivo*, by allowing its recruitment and efficient  
24 histone deposition at DNA synthesis sites.

25 *SpCAF-1(ED\*)* showed a stronger interaction with PCNA than WT-*SpCAF-1 in vivo*, and was  
26 more retained in replication foci (**Figure 6**). This default may not result from a direct competition  
27 between PCNA and histones for CAF-1 association since *SpCAF-1-ED\** and WT-*SpCAF-1* show  
28 similar interaction with DNA and PCNA *in vitro* (**Figure 4, Figure S4**). In human cells lacking new  
29 histones, PCNA accumulates on newly synthesized DNA, and PCNA unloading has recently linked to  
30 histone deposition in budding yeast<sup>32-34</sup>. We propose that the accumulation of CAF-1 at replication foci  
31 in the ED\* mutant may reflect PCNA recycling defects. This cannot be attributed to the inability of  
32 *SpCAF-1(ED\*)* to deposit histones otherwise similar accumulations we should have observed the same  
33 accumulation for *SpCAF-1(ΔWHD)* also defective for histone deposition. The ED\* mutation could rather  
34 interfere with other interactions, or with Post-Translational Modifications (PTMs) contributing to  
35 recycle PCNA.

1 Deletion of the WHD domain allowed separating *SpCAF-1* functions in chromatin assembly,  
2 heterochromatin maintenance and the prevention of DNA damage. Unlike *ScCAF-1*<sup>17,19,23,28</sup> and  
3 *HsCAF-1*<sup>28</sup>, Pcf1\_WHD did not bind DNA nor the ED domain (which remains fully disordered) in the  
4 free chaperone. Nevertheless, on the NMR spectra of the free and histone bound *SpCAF-1*(<sup>15</sup>N-Pcf1),  
5 the resonances of the isolated WHD domain are not present (**Figure 1d, S3n**), in agreement with a  
6 restricted movement of this domain that could likely interacts with other folded parts of the complex. *In*  
7 *vitro*, we found no impact of the WHD deletion on CAF-1 interaction with DNA, histones or PCNA,  
8 but the *SpCAF-1*( $\Delta$ WHD) was deficient for histone deposition. Thus, the synthetic lethality of this  
9 mutant with *hip1* most likely reflects a replication-coupled assembly defect. Unexpectedly, this defect  
10 does not cause a problem of heterochromatin maintenance or damage accumulation, indicating that the  
11 WHD domain contributes to specify CAF-1 functions. Further investigations will be necessary to  
12 understand the role of this domain.

13 We reveal that disorder is a fundamental feature of Pcf1 supporting its molecular functions.  
14 First, the ED domain is disordered in the FL complex and folds upon histone binding. Second, four IDRs  
15 demarcate specific domains within Pcf1. We believe that these unfolded regions provide unique  
16 ‘plasticity’ properties to Pcf1 allowing these domains to bind concomitantly their multiple specific  
17 partners (Pcf1, Pcf3, PCNA, DNA and histones). We also reveal that although these domains  
18 individually bind their specific partners, there is an important crosstalk between them as exemplified by  
19 the fact that DNA stabilizes the CAF-1–PCNA interaction. Such plasticity and cross-talks provided by  
20 structurally disordered domains might be key for the multivalent CAF-1 functions.

21  
22

## 1 **Materials and Methods**

### 2 **Plasmid preparation for recombinant protein production**

3 The cDNA sequence of WT Pcf1 (codon optimized for *E.coli* expression) was synthesized and  
4 inserted into the pCM153 plasmid to obtain the recombinant MBP–6His-TEV cleavage site-Pcf1 protein  
5 (named MBP-Pcf1 below). The cDNA sequence of WT Pcf2 and WT Pcf3 (codon optimized for insect  
6 cells expression) were synthesized and introduced into a pKL plasmid for protein expression in insect  
7 cells (MultiBac approach<sup>35</sup>) with either a C-terminal (for Pcf2) or a N-terminal (for Pcf3) 6His tag with  
8 a TEV cleavage site between the protein and the His tag. Pcf1\_ED (325-396) and Pcf1\_WHD (471-544)  
9 were sub cloned in frame into pET28A-B18R plasmid for expression with a N-terminal 6His-SUMO  
10 tag. Pcf1\_KER (56-170) and Pcf1-KER-PIP (56-185) were inserted in frame into pCM153 plasmid<sup>36</sup>  
11 for expression with a N-terminal 6His-MBP-TEV tag. The cDNA sequence of *S. pombe* histones H3–H4  
12 (codon optimized for *E.coli* expression) were introduced in the 6His-dAsf1 from the pET28 plasmid  
13 (generous gift from R.N. Dutnall) in place of histones *Dm*H3-H4<sup>37</sup>. With this vector, histones H3–H4  
14 are coexpressed with the chaperone ASF1, leading to soluble untagged free-histones, and ASF1-bound  
15 histones. The cDNA of *Sp*PCNA (codon optimized for *E.coli* expression) was synthesized and inserted  
16 into the pET28A-B18R plasmid for expression with an N-terminal 6His-SUMO. Pcf1 mutants were  
17 generated by PCR. All plasmids for recombinant protein expression were constructed by GenScript.

### 18 **Recombinant protein production**

19 Pcf1 was overexpressed in *E.coli*. After fresh transformation of *E. coli* BL21 (DE3) Star cells  
20 (Thermo Fisher Scientific), cells were grown in an auto-induction rich medium Terrific Broth (12 g/L  
21 tryptone, 24 g/L yeast extract) containing 50 µg/mL of Kanamycin for 30 hours at 20°C, under agitation.  
22 *Sp*Histones H3-H4, *Sp*PCNA and the all domains of Pcf1 were overexpressed in *E.coli*. The plasmid for  
23 expressing the desired protein was freshly transformed in *E. coli* strain BL21 DE3 STAR (Thermo  
24 Fisher Scientific). Cells were grown at 37 °C in a LB medium containing 50 µg/mL of Kanamycin until  
25 OD reached 0.7 and recombinant protein expression was induced for 16 hours at 20 °C under agitation  
26 by adding 1 mM isopropyl β-D-1-thiogalactopyranoside IPTG, or cells were grown 30 hours at 20 °C in  
27 a ZY auto-inducible medium. For <sup>15</sup>N or <sup>13</sup>C uniformly labeled proteins, the expression was made in  
28 minimal media with 0.5g/L of <sup>15</sup>NH<sub>4</sub>Cl and/or 2g/L of <sup>13</sup>C-glucose. Pcf2 and Pcf3 were produced in  
29 insect cells. Sf9 Insect cells were infected with an MOI of 5\*10<sup>-3</sup> virus/cell and incubated for 5 days at  
30 27 °C at 130 rpm. After centrifugation, cell pellets stored at -70°C until further use.

31

### 32 **Protein purifications**

#### 33 Purification of Pcf1

34 Cells were pelleted by centrifugation and resuspended in the lysis buffer LB1 for 30 minutes  
35 (50 mM Tris-HCl pH 8, 500 mM NaCl, 5% glycerol, 0.1% Triton X-100, 2 mM DTT, 5 mM MgCl<sub>2</sub>,

1 0.5 mM PMSF, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail, 1.2 mg/mL lysozyme and 70  
2 U/mL of benzonase). Cells were lysed by sonication at 4°C, the lysate was clarified by centrifugation at  
3 5°C at 18 500 rpm for 30min and loaded onto gravity flow amylose resin (NEB) previously equilibrated  
4 with buffer WB1\_1 (50 mM Tris-HCl pH 8, 500 mM NaCl, 2 mM DTT). After loading the cell lysate  
5 onto the resin, the resin was washed with 5 column volumes of buffer WB1\_1 to ensure complete  
6 passage of the cell lysate through the resin. Then, the resin was further washed with 10 column volumes  
7 of buffer WB1\_2 (50 mM Tris-HCl pH 8, 1000 mM NaCl, 2 mM DTT) to remove non-specific  
8 binding, before re-equilibration with 10 column volumes of buffer WB1\_1. MBP-Pcf1 was eluted with  
9 10 column volumes of buffer EB1 (50 mM Tris-HCl pH 8, 500 mM NaCl, 0.5 mM TCEP, 10 mM  
10 maltose and 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail,). After addition of 1 mM MgCl, the  
11 eluate containing MBP-Pcf1 was incubated 16 hours at 5°C with TEV protease (added with a ratio 1/20  
12 in mass). The elate was then concentrated to 300µL (with Amicon® Ultra-15 30kDa filter  
13 concentrators), 2000 U of benzonase were added and incubated for 2 hours. The concentrated eluate was  
14 injected into a column Superose™ 6 increase 10/300 GL (Cytiva) previously equilibrated with the final  
15 buffer FB1 (50 mM Tris-HCl pH 8, 500 mM NaCl, 1 mM DTT). The Pcf1-containing fractions were  
16 pooled. 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail, 0.5 mM TCEP and 30% glycerol was  
17 added and samples were snap-frozen and stored at -70°C.

18

## 19 Purification of Pcf2

20 Cells pellets were resuspended into lysis buffer LB2 (50 mM Tris-HCl pH 8, 500 mM NaCl,  
21 5% glycerol, 0.1% Triton X-100, 10 mM imidazole, 0.5 mM PMSF, cOmplete™ EDTA-free Protease  
22 Inhibitor Cocktail and 70 U/mL of benzonase) and sonicated at 4°C. Lysates were clarified by  
23 centrifugation at 5 °C at 18 500 rpm for 30 min and loaded to gravity flow Ni-NTA agarose resin  
24 (QIAGEN) previously equilibrated with wash buffer WB2\_1 (50 mM Tris-HCl pH 8, 500 mM NaCl,  
25 10 mM imidazole,). Resin was then washed with 10 column volumes of wash buffer WB2\_1 followed  
26 by 10 column volumes of wash buffer WB2\_2 (50 mM Tris-HCl pH 8, 1M NaCl, 10 mM imidazole).  
27 Pcf2-6His was eluted with 5 column volumes of the elution buffer EB2 (50 mM Tris-HCl pH 8, 500  
28 mM NaCl, 250 mM imidazole, 0.5 mM TCEP, and 1X cOmplete™ EDTA-free Protease Inhibitor  
29 Cocktail). The eluate was then concentrated to 300 µL (with Amicon® Ultra-15 30 kDa filter  
30 concentrators). 1 mM DTT, 1 mM MgCl and ≈2000 U of benzonase were added to the concentrated  
31 eluate and the sample was incubated 2 hours at 4 °C and injected into a Superdex 200 increase 10/300  
32 (Cytiva) previously equilibrated with the final buffer FB2 (50 mM Tris-HCl pH 8, 500 mM NaCl and 1  
33 mM DTT). Pcf2-6His containing fractions were pooled and directly used for CAF-1 reconstitution or  
34 stored at -70 °C with cOmplete™ EDTA-free Protease Inhibitor Cocktail, 0.5 mM TCEP and 30%  
35 glycerol.

## 1 Purification of Pcf3

2 Cells pellets were resuspended into lysis buffer LB3 (50 mM Tris-HCl pH 8, 200 mM NaCl,  
3 5% glycerol, 0.1% Triton X-100, 10 mM imidazole, 0.5 mM PMSF, cOmplete™ EDTA-free Protease  
4 Inhibitor Cocktail and 70 U/mL of benzonase) and sonicated at 4°C. Lysate was clarified by  
5 centrifugation at 5 °C at 18500 rpm for 30 min and loaded to gravity flow Ni-NTA agarose resin  
6 (QIAGEN) previously equilibrated with wash buffer WB3\_1 (50 mM Tris-HCl pH 8, 200 mM NaCl,  
7 10 mM imidazole). Resin was then washed with 5 column volumes of wash buffer WB3\_1 and 10  
8 column volumes of wash buffer WB3\_2 (50 mM Tris-HCl pH 8, 200 mM NaCl, 30 mM imidazole).  
9 his-Pcf3 was then eluted with EB3 (50 mM Tris-HCl pH 8, 200 mM NaCl, 250 mM imidazole, 1 mM  
10 DTT, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail). After addition of 1 mM MgCl<sub>2</sub>, 6His-  
11 TEV protease (with a ratio 1/10 in mass), ≈2000 U of benzonase the eluate was dialysed o/n at 5 °C in  
12 the final buffer FB3 (50 mM Tris-HCl pH 8, 200 mM NaCl and 1 mM DTT). Because of their similar  
13 size, Pcf3 and 6His-TEV protease cannot be completely separated by size-exclusion chromatography.  
14 Therefore, to remove the 6His-TEV protease and uncleaved His-Pcf3, 30 mM of imidazole was added  
15 to the dialysate, which was then loaded to gravity flow Ni-NTA agarose resin (QIAGEN) previously  
16 equilibrated with wash buffer WB3\_2. The Flow through was concentrated to 300μL (with Amicon®  
17 Ultra-15 30 kDa filter concentrators) and injected into a Superdex 200 increase 10/300 (Cytiva)  
18 previously equilibrated with the final buffer FB3. Pcf3-containing fractions were pooled and stored at -  
19 70 °C after adding 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail, 0.5 mM TCEP and 30%  
20 glycerol.

## 21 Reconstitution of CAF-1 complexes

22 CAF-1 complexes were formed by mixing the isolated proteins Pcf1 (WT or mutant), Pcf2-6His  
23 and Pcf3 previously purified as described above. Isolated Pcf2-6His and Pcf3 were added in small excess  
24 compared to Pcf1. Tris 50 mM pH 8 was added to the Pcf1/Pcf2-his/Pcf3 mix to reach a final NaCl  
25 concentration of 150mM. After addition of 1 mM MgCl<sub>2</sub>, 1X cOmplete™ EDTA-free Protease Inhibitor  
26 Cocktail, 6His-TEV protease (with a ratio 1/10 in mass) and ≈2000 U of benzonase, the mixture was  
27 incubated over night at 4 °C and applied on a HiTrap® heparin FF column (Cytiva) previously  
28 equilibrated with EB4\_1 (50 mM Tris-HCl pH 8, 100 mM NaCl). A gradient was applied with the high  
29 salt buffer EB4\_2 (50 mM Tris-HCl pH 8, 1M NaCl). Fractions containing the full *Sp*CAF-1 were  
30 pooled, concentrated to 300μL (with Amicon® Ultra-15 30 kDa filter concentrators) and injected into a  
31 Superdex 200 increase 10/300 (Cytiva) previously equilibrated with the final buffer FB4\_1 (50 mM  
32 Tris-HCl pH 8, 150 mM NaCl and 1 mM DTT). The *Sp*CAF-1-containing fractions were pooled and  
33 directly used for MST or EMSA analysis or stored at -70°C with 1X cOmplete™ EDTA-free Protease  
34 Inhibitor Cocktail, 0,5 mM TCEP and 30% glycerol.

1           The *SpCAF-1*(<sup>15</sup>N-<sup>13</sup>C-Pcf1) and *SpCAF-1*(<sup>15</sup>N-Pcf1) was reconstituted by co-lysing the pellets  
2 of <sup>15</sup>N-<sup>13</sup>C-MBP-Pcf1 or <sup>15</sup>N-MBP-Pcf1 (WT or mutants), Pcf2-6His and his-Pcf3. Cell pellets from  
3 Pcf2-6His and Pcf3-his were added in excess compared to labeled MBP-Pcf1, based on the yield  
4 previously obtained for the isolated proteins. The pellets were resuspended and mixed in the lysis buffer  
5 LB4 (50 mM Tris-HCl pH 8, 150 mM NaCl, 5% glycerol, 0.1% Triton X-100, 10 mM imidazole, 0.5  
6 mM PMSF, cOmplete™ EDTA-free Protease Inhibitor Cocktail and 70 U/mL of benzonase), sonicated  
7 and centrifuged as described before. The clarified lysate was applied to gravity flow Ni-NTA agarose  
8 resin (QIAGEN) previously equilibrated with wash buffer WB4\_1 (50 mM Tris-HCl pH 8, 150 mM  
9 NaCl, 10 mM imidazole). Beads were washed with 5 column volume of WB4\_1 buffer, followed by 10  
10 column volumes of WB4\_2 (50 mM Tris-HCl pH 8, 1 M NaCl, 10 mM imidazole). Elution was  
11 performed with EB4 (50 mM Tris-HCl pH 8, 150 mM NaCl, 250 mM imidazole, 1X cOmplete™ EDTA-  
12 free Protease Inhibitor Cocktail) and applied to an anion exchange column HiTrap® Q FF (Cytiva)  
13 previously equilibrated with buffer EB4\_1. A gradient was applied with the high salt buffer EB4\_2. The  
14 tagged CAF-1-containing fractions were pooled, and dialyzed overnight against buffer 4 DB4 (Tris 50  
15 mM pH 8, 150 mM NaCl, 1 mM DTT) after addition of 1 mM DTT, 1 mM MgCl<sub>2</sub>, 1X cOmplete™  
16 EDTA-free Protease Inhibitor Cocktail, 6His-TEV protease (with a ratio 1/10 in mass) and ≈2000 U of  
17 benzonase. The mixture was applied on a HiTrap® heparin FF column (Cytiva) using the same buffers  
18 (EB4\_1 and EB4\_2). The *SpCAF-1*(<sup>15</sup>N-<sup>13</sup>C/<sup>15</sup>N-Pcf1) -containing fractions were concentrated to 300μL  
19 (with Amicon® Ultra-15 30 kDa filter concentrators) and injected into a Superdex 200 increase 10/300  
20 (Cytiva) previously equilibrated with buffer FB4\_2 (10 mM Tris-HCl, 50 mM HEPES pH 7, 300 mM  
21 NaCl and 0.5 mM TCEP). The *SpCAF-1*(<sup>15</sup>N-<sup>13</sup>C-Pcf1)-containing fractions were pooled and  
22 immediately used for NMR measurements.

### 23 Purification of histones *SpH3*–*SpH4*

24           Cells expressing *SpH3*, *SpH4* with 6His-dAsf1 were pelleted by centrifugation and resuspended  
25 in the lysis buffer LB5 (50 mM Tris-HCl pH 8, 500 mM NaCl, 5% glycerol, 1% Triton X-100, 1 mM  
26 DTT, 10 mM MgCl<sub>2</sub>, 0.5 mM PMSF, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail) and flash  
27 frozen in liquid nitrogen. After thawing, lysozyme and benzonase were added at a final concentration  
28 of 0.25 mg/mL and 70 U/mL respectively. After incubation 20 minutes at 4°C, cells were lysed by  
29 sonication. Soluble 6His-Asf1 was removed on a NiNTA column (Qiagen) equilibrated in the LB5  
30 buffer. The flow through (containing soluble free histones) was filtered with 0.22 μ filters and loaded  
31 on a cation exchange Resource S column (GE Healthcare) equilibrated with the dilution buffer EB5\_1  
32 (50 mM Tris-HCl pH8). Histones H3–H4 were eluted with a NaCl gradient in a buffer EB5\_2 (50 mM  
33 Tris-HCl pH8, 2 M NaCl). The H3–H4-containing fractions were pooled, the salt concentration adjusted  
34 to 2 M NaCl, and concentrated in a 3 kDa concentrator (Millipore), flash freezed in liquid nitrogen and  
35 stored at -70°C.

### 36 Purification of Pcf1\_ED and Pcf1\_ED\*

1 Cells expressing Pcf1\_ED or Pcf1\_ED\* with a N-terminal 6His-SUMO tag were collected by  
2 centrifugation, resuspended in lysis buffer LB6 (50 mM Tris-HCl pH8, 500 mM NaCl, 5% glycerol, 1%  
3 Triton X-100, 1 mM PMSF, 1  $\mu$ M aprotinin, 0.25 mM DTT) and flash frozen in liquid nitrogen. After  
4 thawing, lysosome was added at a final concentration of 1 mg/mL and cells were incubated 30 min at  
5 4 °C and lysed by sonication. 6His-SUMO-Pcf1\_ED was first purified on Histrap columns (Cytiva).  
6 Fractions containing the protein were pulled. SUMO protease was added at a final concentration 1/10  
7 and the mixture was dialyzed overnight at 4 °C against the buffer DB6 (50 mM Tris-HCl pH 8, 150 mM  
8 NaCl, 10 mM imidazole) and applied on a NiNTA column (Qiagen) equilibrated in the DB6 buffer. The  
9 flow-through fraction containing Pcf1\_ED or Pcf1\_ED\*\_was then purified by size exclusion  
10 chromatography using a Superdex 75 increase 10/300 column (Cytiva) previously equilibrated with the  
11 final buffer in FB6 (10 mM Tris-HCl, 50 mM HEPES pH 7, 300 mM NaCl). Fraction containing  
12 Pcf1\_ED or Pcf1\_ED\* were concentrated using Amicon centrifuge filter units of 3 kDa cutoff  
13 (Millipore) flash frozen in liquid nitrogen and stored at -20 °C or -70 °C.

#### 14 Purification of Pcf1\_KER and Pcf1\_KER-PIP

15 Cells expressing Pcf1\_KER(56-170), or Pcf1-KER-PIP(56-185) (WT or mutant) with a N-  
16 terminal 6His-MBP-TEV tag were collected by centrifugation, resuspended in lysis buffer LB7 (50 mM  
17 Tris-HCl pH 8, 500 mM NaCl, 5% glycerol, 1% Triton X-100, 1 mM PMSF, 1  $\mu$ M aprotinin, 0.25 mM  
18 DTT, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail) and flash frozen in liquid nitrogen. After  
19 thawing, 5 mM MgCl<sub>2</sub>, 1 mg/mL lysozyme and 70 U/mL of benzonase were added and cells were lysed  
20 by sonication. Proteins were first purified on Histrap columns (Cytiva) including a wash step with WB7  
21 (50 mM Tris-HCl pH 8, 1000 mM NaCl). 1 mM DTT and TEV protease (1/10 ratio) was added to the  
22 fractions containing the 6His-MBP-TEV\_ Pcf1\_KER fragment and the mixture was incubated 2 hours  
23 at room temperature and injected on a resource S column (Cytiva) previously equilibrated with EB7\_1  
24 (50 mM Tris-HCl pH 8). A gradient was applied with the high salt buffer EB7\_2 (50 mM Tris-HCl pH  
25 8, 2M NaCl). Fractions containing Pcf1\_KER fragment were pooled and diluted to reach a concentration  
26 of 150 mM NaCl and concentrated (with Amicon® Ultra-10 kDa filter concentrators).

#### 27 Purification of Pcf1\_WHD

28 Cells expressing Pcf1\_WHD with a N-terminal 6His-SUMO tag were resuspended in lysis buffer  
29 LB8 (50 mM Tris-HCl pH8, 500 mM NaCl, 5% glycerol, 1% Triton X-100, 1 mM PMSF, 1  $\mu$ M  
30 aprotinin, 0.25 mM DTT, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail) and flash frozen in  
31 liquid nitrogen. After thawing, 5 mM MgCl<sub>2</sub>, 1 mg/mL lysozyme and 70 U/mL of benzonase was added  
32 and cells were further lysed by sonication. The lysate was loaded onto gravity flow amylose resin (NEB)  
33 previously equilibrated with buffer WB8\_1 (50 mM Tris-HCl pH 8). Resin was then washed with 10  
34 column volume of buffer WB8\_1, 10 column volumes of buffer WB8\_2 (50 mM Tris-HCl pH 8, 1000  
35 mM NaCl), 10 column volumes of buffer WB8\_1. 6His-SUMO- Pcf1\_WHD was eluted with 10 column



1 volume of buffer EB8 (50 mM Tris-HCl pH 8, 500 mM NaCl, 250 mM Imidazole). SUMO protease  
2 was added at a final concentration 1/10 and the mixture was incubated overnight at 4°C. The mixture  
3 was concentrated (with Amicon® Ultra-3 kDa filter concentrators) and applied on a Superdex 75  
4 increase 10/300 size exclusion column (Cytiva) previously equilibrated with the final buffer FB8 (10  
5 mM Tris-HCl, 50 mM HEPES pH7, 150 mM, NaCl). Finally, proteins were concentrated in a 3 kDa  
6 concentrator (Millipore).

### 7 Purification of *SpPCNA*

8 Cells expressing *SpPCNA* with a N-terminal 6His-SUMO tag were resuspended in lysis buffer  
9 LB9 (50 mM Tris-HCl pH8, 500 mM NaCl, 5% glycerol, 1% Triton X-100, 1 mM PMSF, 1 µM  
10 aprotinin, 0.25 mM DTT, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail) and flash frozen in  
11 liquid nitrogen. After thawing, 1 mM MgCl<sub>2</sub>, 1 mg/mL lysozyme and 70 U/mL of benzonase was added  
12 and cells were further lysed by sonication. The lysate was loaded onto gravity flow amylose resin (NEB)  
13 previously equilibrated with buffer WB9\_1 (50 mM Tris-HCl pH 8). Resin was then washed with 10  
14 column volume of buffer WB9\_1, 10 column volumes of buffer WB8\_2 (50 mM Tris-HCl pH 8, 2000  
15 mM NaCl), 10 column volumes of buffer WB8\_1. 6His-SUMO-*SpPCNA* was eluted with 3 column  
16 volumes of buffer EB9 (50 mM Tris-HCl pH 8, 250 mM Imidazole). 1mM DTT and SUMO protease  
17 was added at a final concentration 1/10 and the mixture was dialyzed overnight at 4°C against the buffer  
18 DB9 (50 mM Tris-HCl pH 8, 150 mM NaCl, 10 mM imidazole). The mixture was applied on a Histrap  
19 column (Cytiva), the flow through (containing *SpPCNA*) was concentrated (with Amicon® Ultra-15 3  
20 kDa filter concentrators) and applied on a hiLoad 16/600 superdex 200 size exclusion column previously  
21 equilibrated with a FB9 (50 mM Tris-HCl pH8, 150 mM NaCl). In case the digestion of the tag was  
22 incomplete, the two last steps digestion with SUMO protease and gel filtration were repeated.

23 For all protein samples, depending on specific requirements of different techniques used, aliquots  
24 of concentrated protein were either maintained at 4°C or flash frozen in liquid nitrogen after addition or  
25 not of 30% glycerol and stored at -70°C for further use.

### 26 **DNAs used to monitor protein-DNA interactions**

27 The different DNAs were purchased from eurofins genomics. The sequences were derived from  
28 the 601 positioning sequence: ATCAATATCCACCTGCAGATACTACCAAAAGTGTATTTGG. For  
29 MST, the DNA were labeled with ALEXA488 at their 5' extremity. The ssDNA was annealed with the  
30 reverse-complementary sequence by heating at 90 °C and cooling slowly at room temperature.

### 31 **Size-exclusion chromatography (SEC)**

32 *SpCAF-1* subunits interaction was performed by mixing 2.2 nmoles of each isolated protein  
33 together in a final volume of 1.26 mL and left o/n at 5°C. The complexes were then concentrated to  
34 300µL (with Amicon® Ultra-15 30 kDa filter concentrators) and injected into a Superdex 200 increase  
35 10/300 (Cytiva) for separation by size-exclusion chromatography previously equilibrated with the

1 FB4\_3 (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM DTT). The different fractions were analyzed  
2 on mPAGE® 8% Bis-Tris Precast Gels (Sigma) with MOPS SDS running buffer. Interaction between  
3 CAF-1 and H3–H4 was carried out by incubating for 3 hours, 3 nmoles of *Sp*CAF-1 with 3 nmoles of  
4 *Sp*H3–H4 in a final buffer FB4\_4 (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM DTT, 1X  
5 cOmplete™ EDTA-free Protease Inhibitor Cocktail) or FB4\_5 (50 mM Tris-HCl pH 7.5, 1 M NaCl,  
6 4 mM DTT, 1X cOmplete™ EDTA-free Protease Inhibitor Cocktail). Samples were then  
7 concentrated to 300µL (with Amicon® Ultra-15 30 kDa filter concentrators) and injected into a  
8 Superdex 200 increase 10/300 (Cytiva) for separation by size-exclusion chromatography with their  
9 corresponding buffers. The different fractions were analyzed on mPAGE® 4-20% Bis-Tris Precast Gels  
10 (Sigma) with MES SDS running buffer.

### 11 **Electrophoretic Mobility Shift Assay (EMSA)**

12 The proteins and DNA were mixed to be in a final EMSA buffer EMB (25 mM Tris-HCl pH 8, 1  
13 mM EDTA pH 8.0, 150 mM NaCl) and incubated at 4 °C for 30 min and heated at 37 °C for 5 min prior  
14 to analysis on precast “any KD” Mini-PROTEAN TGX (Bio-rad, Cat #4569033) polyacrylamide gels  
15 using 1x TBE as running buffer. The gels were stained with 1x of SYBR Safe (Thermo Fisher Scientific,  
16 Waltham, MA) then visualized with BIORAD EZ Imager. A second identical the gel was Coomassie  
17 Blue before being visualized with the BIORAD EZ Imager. Band intensities were quantified by ImageJ.

### 18 **MicroScale Thermophoresis (MST)**

19 DNAs labeled with ALEXA488 at their 5' extremity. The final dilution buffer was FB\_MST (10  
20 mM Tris-HCl, 40 mM HEPES pH 7, 150 mM NaCl). The labeled DNA was adjusted to 20 nM. Freshly  
21 prepared proteins or complexes were diluted in the same buffer with 16 serial dilution 1:2. Each protein  
22 dilution was mixed with one volume of labeled DNA and filled into Monolith NT standard treated  
23 capillaries (NanoTemper Technologies GmbH). Thermophoresis was measured using a Monolith  
24 NT.115 instrument (NanoTemper Technologies GmbH) at an ambient temperature of 20 °C with 3-s/20-  
25 s/1-s laser off/on/off times, respectively. Instrument parameters were adjusted with 80% LED power  
26 and 40% MST power. Data of two measurements were analyzed (MO.Affinity Analysis software,  
27 NanoTemper Technologies) using the signal from thermophoresis at 5s.

### 28 **Circular Dichroism (CD)**

29 Circular Dichroism (CD) measurements were carried out at 20 °C on a JASCO J-810 spectro-  
30 polarimeter. Temperature was controlled by a Peltier. Spectra from 190 to 250 nm were obtained using  
31 a 2 mm optical path length quartz cell (Hellma #100-2-40) containing Pcf1\_KER or Pcf1\_KER\* (5µM)  
32 in 10 mM of phosphate buffer (pH 7.4).

### 33 **Nuclear Magnetic Resonance (NMR)**

1 NMR experiments were carried out on Bruker DRX-600 MHz, 700 MHz or 950MHz  
2 spectrometers equipped with cryo-probes. All NMR data were processed using Topspin (Bruker) and  
3 analyzed using Sparky (T.D. Goddard and D.G. Kneller, UCSF). Samples were prepared in 3 mm NMR  
4 tubes, in solution containing 5% D<sub>2</sub>O, 0.1% Na<sub>3</sub>N, 0.1 mM DSS with different buffer appropriate for  
5 different complex formations or reactions. Heteronuclear Multiple Quantum Correlation (sofast-  
6 HMQC) or best-HSQC spectra were all recorded at 283°K. The protein concentrations were between 9  
7 μM and 500 μM. For backbone resonances assignments, 3D data were collected at 283°K using standard  
8 Heteronuclear Single Quantum Correlation (HSQC) spectra <sup>1</sup>H-<sup>15</sup>N HSQC, TOCSY-HSQC, HNCA,  
9 HBHA(CO)NH, CBCA(CO)NH, HN(CA)CO, HNCO, HN(CO)CA, CBCANH and HN(CA)CO  
10 experiments. Proton chemical shifts (in ppm) were referenced relative to internal DSS and <sup>15</sup>N and <sup>13</sup>C  
11 references were set indirectly relative to DSS using frequency ratios<sup>38</sup>. Chemical shift index were  
12 calculated according to the sequence-specific random coil chemical shifts<sup>39,40</sup>.

13 Structural models of the *Sp*CAF-1 WHD domain were computed from NMR data with CS-ROSETTA<sup>41</sup>  
14 version 1.01. First, the MFR program from NMRpipe<sup>42</sup> was used to search a structural database for best  
15 matched fragments based on the protein backbone <sup>15</sup>N, <sup>13</sup>C, <sup>13</sup>CA, <sup>13</sup>CB and <sup>1</sup>HN chemical shifts. Then  
16 the ROSETTA 3.8 software was used to generate 27753 models by fragment assembly and full-atom  
17 relaxation. These models were rescored by comparing the experimental chemical shifts with the  
18 chemical shifts predicted by SPARTA<sup>43</sup> for each model. The best model after rescoring was chosen as  
19 a representative NMR model of the WHD domain.

## 20 **Small Angle Xray Scattering (SAXS)**

21 SAXS data were collected at the SWING beamline on a EigerX 4 M detector using the standard  
22 beamline setup in SEC mode<sup>44</sup>. Samples were injected into a Superdex 5/150 GL (Cytivia) column  
23 coupled to a high-performance liquid chromatography system, in front of the SAXS data collection  
24 capillary. The initial data processing steps including masking and azimuthal averaging were performed  
25 using the program FOXTROT<sup>45</sup> and completed using US-SOMO<sup>46</sup>. The final buffer subtracted and  
26 averaged SAXS profiles were analyzed using ATSAS v.3. software package<sup>47</sup>. To model the structures  
27 and improve the AlphaFold2 models, the program Dadimodo<sup>48</sup> (<https://dadimodo.synchrotron-soleil.fr>)  
28 that refines multidomain protein structures against experimental SAXS data was used (see **Table S1** in  
29 supplementary data for more information).

## 30 **Structural Modeling**

31 Sequences of *S. pombe* Pcf1 (Q1MTN9), Pcf2 (O13985), Pcf3 (Q9Y825), H3 (P09988), H4 (P09322)  
32 and PCNA (Q03392) were retrieved from UniProt database<sup>49</sup>. These sequences were used as input of  
33 mmseqs2 homology search program<sup>50</sup> used with three iterations to generate a multiple sequence  
34 alignment (MSA) against the uniref30\_2103 database<sup>51</sup>. The resulting alignments were filtered using  
35 hhfilter<sup>52</sup> using parameters ('id'=100, 'qid'=25, 'cov'=50) and the taxonomy assigned to every sequence

1 keeping only one sequence per species. To increase the number of sequences in the alignment of *S.*  
2 *pombe* Pcf1 we independently generated MSA using mmseqs2 starting from the *S. cerevisiae* or the  
3 human homolog of Pcf1 (Q12495 and Q13111, respectively) and the resulting alignments were  
4 combined with the one of *Sp*Pcf1. Full-length sequences in the alignments were then retrieved and the  
5 sequences were realigned using MAFFT<sup>53</sup> with the default FFT-NS-2 protocol. To build the so-called  
6 mixed co-alignments, sequences in the alignment of individual partners were paired according to their  
7 assigned species and left unpaired in case no common species were found<sup>51</sup>. A first global model with  
8 full-length Pcf1, Pcf2 and Pcf3 was generated to map the regions of Pcf1 binding to Pcf2 and Pcf3 and  
9 to obtain the pLDDT scores shown in **Figure 1b** for Pcf1, **Figure S1f** for Pcf2 and Pcf3. Next, three  
10 models of the complex corresponding to independent modules of the complex were generated using  
11 different delimitations: model\_1 (presented in **Figure S1g-i**) with Pcf1(403-450)-Pcf2(1-453) (MSA  
12 with 2180 species, 501 positions), model\_2 (presented in **Figure S1j-l**) with Pcf1(200-335)-Pcf3(1-408)  
13 (MSA with 2148 species, 544 positions), model\_3 Pcf1(352-383)-H3(60-136)-H4(25-103) (presented  
14 in **Figure 2f and S2d**) (MSA with 3530 species, 188 positions). Concatenated mixed MSAs were  
15 generated using the delimitations defined above and used as input to run 5 independent runs of the  
16 Alphafold2 algorithm with 6 iterations each<sup>54</sup> generating 5 structural models using a local version of the  
17 ColabFold interface<sup>51</sup> trained on the multimer dataset<sup>55</sup> on a local HPC equipped with NVIDIA Ampere  
18 A100 80Go GPU cards. The best models of each of the 5 runs converged toward similar conformations.  
19 They reached high confidence and quality scores with pLDDTs in the range [83.7, 84.3], [88.8, 89.8]  
20 and [86.5, 88.4] and the model confidence score (weighted combination of pTM- and ipTM-scores with  
21 a 20:80 ratio)<sup>55</sup> in the range [0.9, 0.93], [0.88, 0.89], [0.85, 0.87], for model\_1, model\_2 and model\_3,  
22 respectively. The models with highest confidence score for each of the three models were relaxed using  
23 rosetta relax protocols to remove steric clashes<sup>56</sup> with constraints (std dev. of 2 Å for the interatomic  
24 distances) and were used for structural analysis. MSA web logos were generated with the weblogo server  
25 (<https://weblogo.berkeley.edu/logo.cgi>).

## 26 **Nucleosome assembly assay**

27 Mock- and p150CAF-1-depleted *Xenopus* high speed egg extract (HSE) were prepared as  
28 previously<sup>24</sup>. Nucleosome assembly was performed on pBS plasmid damaged by UV (500J/m<sup>2</sup>) to  
29 promote DNA synthesis as previously described<sup>24</sup> except that the reaction mixed contained 3.2 μM of  
30 biotin-14-dCTP (Invitrogen, Ref 19518-0189) instead of [ $\alpha^{32}$ P]-dCTP. The p150CAF-1-depleted  
31 extracts were complemented with 50 ng of isolated/reconstituted spCAF-1 complex composed of WT  
32 or mutated Pcf1. After DNA purification, samples were by processed for gel electrophoresis (1%  
33 agarose) to resolve topoisomers as previously described<sup>24</sup>. After staining with Ethidium bromide to  
34 visualize total DNA and gel transfer on a Nylon N+ membrane (GE Healthcare Ref RPN203B)  
35 (Qbiogen) for 45 min at 40 mbar in 10x SSC, the membrane was rinsed in PBS, air dried and DNA was  
36 crosslinked to the membrane using Stratilinker (Biorad). DNA synthesis was visualized by detecting

1 biotin with the Phototope-Star detection kit (New England Biolabs Ref N7020S) and images acquired  
2 on a Chemidoc system (Biorad).

### 3 **Standard yeast genetics**

4 Yeast strains were freshly thawed from frozen stocks and grown at 30 °C using standard yeast genetics  
5 practices. The *pcf1* mutants were obtained by classical genetic techniques. Yeast strains used in this  
6 study are listed in Supplementary **Table S2**.

### 7 **Peri-centromeric silencing assay**

8 5-FOA (EUROMEDEX, 1555) resistant colonies were grown on uracil-containing liquid media  
9 overnight and 10 µL of 5 fold serial dilutions (from 1.10<sup>7</sup> cells/mL to 1.10<sup>5</sup> cells/ml) were spotted on  
10 indicated media.

### 11 **Co-immunoprecipitation.**

12 5.10<sup>8</sup> cells from exponentially growing cultures were harvested with 10% NaN<sub>3</sub> and 1 mM PMSF, final  
13 concentration, and then washed twice in water and once in Lysis buffer (buffer (50 mM HEPES High  
14 salt, 50 mM KoAc pH7.5, 5 mM EGTA, 1% triton X100, 0.01mg/mL AEBSF, EDTA-free protease  
15 inhibitor cocktail). Cell pellets were resuspended in 800 µL of lysis buffer and were broken with a  
16 Precellys homogenizer (twice 4 cycles at 10 000 rpm, 20 sec-2 min pause). After lysate clarification (30  
17 minutes at 13 000 rpm, 4°C), 2.5 mg of proteins were incubated with pre-washed Dynabeads protein G  
18 (Invitrogen, 10003D) coupled to anti-FLAG antibody (Sigma F7425) and incubated overnight at 4 °C  
19 on a wheel. Beads were washed three times for 5 minutes at 4 °C with 800 µL of lysis buffer, and then  
20 resuspended in 1X Laemmli buffer, and boiled at 95 °C for 10 minutes. INPUT and UNBOUND (both  
21 10 % of initial protein extract) and BOUND (IP) fraction were resolved by electrophoresis on acrylamide  
22 gels (4-12% Invitrogen) and the transferred onto nitrocellulose membrane that were saturated for 1 hour,  
23 RT in TBS-0.075% tween-5% milk. Proteins of interest were detected with anti-FLAG antibody (Sigma  
24 F1805, 1:1000) and anti-PCNA antibody (Santa Cruz sc-8349, 1:500).

### 25 **Live cell imaging**

26 All image acquisition was performed on the PICT-IBiSA Orsay Imaging facility of Institut Curie. For  
27 snapshot microscopy, cells were grown in filtered supplemented EMM-glutamate, with or without  
28 thiamine respectively, for 24 hours. Exponentially growing cultures were centrifuged and resuspended  
29 in 50 µL of fresh medium. 2 µL from this concentrated solution was dropped onto a Thermo Scientific  
30 slide (ER-201B-CE24) covered with a thin layer of 1.4 % agarose in filtered EMMg. 13 z-stack pictures  
31 (each z step of 300 nm) were captured using a Spinning Disk Nikon inverted microscope equipped with  
32 the Perfect Focus System, Yokogawa CSUX1 confocal unit, Photometrics Evolve512 EM-CCD camera,  
33 100X/1.45-NA PlanApo oil immersion objective and a laser bench (Errol) with 491 (GFP) and 561  
34 (MmCherry) nm diode lasers, 100 mX (Cobolt). Pictures were collected with METAMORPH software

1 and analyzed with ImageJ. For Pcf2-GFP and Rad52-GFP foci, a threshold (find maxima) was setup at  
2 the same level for each genetic background analyzed within the same experiment.

3

#### 4 **Data availability**

5 We deposited structural models generated by AlphaFold2 at the modelarchive repository site  
6 (<https://www.modelarchive.org/doi/10.5452/ma-1bb5w>,  
7 <https://www.modelarchive.org/doi/10.5452/ma-bxxkp>, [https://www.modelarchive.org/doi/10.5452/ma-](https://www.modelarchive.org/doi/10.5452/ma-htx0n)  
8 [htx0n](https://www.modelarchive.org/doi/10.5452/ma-htx0n) )

#### 9 **Acknowledgements:**

10 We thank the Alain LECOQ and Denis SERVENT from giving access to the CD spectro-polarimeter.  
11 This work was supported by grants from the INCA (2016-1-PL BIO-03-CEA-1, 2016-1-PLBIO-03-  
12 ICR-1), ANR (ANR-16-CE11-0028; ANR-20-CE18-0038; ANR-21-CE11-0027; ANR-21-CE44-0009-  
13 01) the program labeled by the ARC foundation 2016 (PGA1\*20160203953), , the Fondation LIGUE  
14 “Equipe Labellisée 2020” (EL2020LNCC/Sal), and by french infrastructures, the Synchrotron Soleil  
15 (20191119; 20210745), the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-  
16 INBS-0005 and the IR INFRANALYTICS FR2054. It benefited from the ERC-2015-ADG-694694  
17 “ChromADICT”, the Ligue Nationale contre le Cancer (Equipe labellisée Ligue) and ANR-11-LABX-  
18 0044 5. We also thank the PICT-IBiSA@Orsay Imaging Facility of the Institut Curie (particularly  
19 Laetitia Besse).

20

#### 21 **References**

- 22 1 Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F. & Richmond, T. J. Crystal structure  
23 of the nucleosome core particle at 2.8 Å resolution. *Nature* **389**, 251-260, doi:10.1038/38444  
24 (1997).
- 25 2 Gurard-Levin, Z. A., Quivy, J. P. & Almouzni, G. Histone chaperones: assisting histone traffic  
26 and nucleosome dynamics. *Annu Rev Biochem* **83**, 487-517, doi:10.1146/annurev-biochem-  
27 060713-035536 (2014).
- 28 3 Ray-Gallet, D. & Almouzni, G. H3-H4 histone chaperones and cancer. *Curr Opin Genet Dev*  
29 **73**, 101900, doi:10.1016/j.gde.2022.101900 (2022).
- 30 4 Yi, S. J. & Kim, K. New Insights into the Role of Histone Changes in Aging. *Int J Mol Sci* **21**,  
31 doi:10.3390/ijms21218241 (2020).
- 32 5 Sultana, S., Zarreen, F. & Chakraborty, S. Insights into the roles of histone chaperones in  
33 nucleosome assembly and disassembly in virus infection. *Virus Res* **297**, 198395,  
34 doi:10.1016/j.virusres.2021.198395 (2021).
- 35 6 Smith, S. & Stillman, B. Purification and characterization of CAF-I, a human cell factor required  
36 for chromatin assembly during DNA replication in vitro. *Cell* **58**, 15-25 (1989).
- 37 7 Loyola, A. & Almouzni, G. Histone chaperones, a supporting role in the limelight. *Biochim*  
38 *Biophys Acta* **1677**, 3-11, doi:10.1016/j.bbaexp.2003.09.012 (2004).
- 39 8 Ridgway, P. & Almouzni, G. CAF-1 and the inheritance of chromatin states: at the crossroads  
40 of DNA replication and repair. *J Cell Sci* **113 ( Pt 15)**, 2647-2658 (2000).

- 1 9 Martini, E., Roche, D. M., Marheineke, K., Verreault, A. & Almouzni, G. Recruitment of  
2 phosphorylated chromatin assembly factor 1 to chromatin after UV irradiation of human cells.  
3 *J Cell Biol* **143**, 563-575 (1998).
- 4 10 Moggs, J. G. *et al.* A CAF-1-PCNA-mediated chromatin assembly pathway triggered by sensing  
5 DNA damage. *Molecular and cellular biology* **20**, 1206-1218 (2000).
- 6 11 Rolef Ben-Shahar, T. *et al.* Two fundamentally distinct PCNA interaction peptides contribute  
7 to chromatin assembly factor 1 function. *Molecular and cellular biology* **29**, 6353-6365,  
8 doi:10.1128/MCB.01051-09 (2009).
- 9 12 Pietrobon, V. *et al.* The chromatin assembly factor 1 promotes Rad51-dependent template  
10 switches at replication forks by counteracting D-loop disassembly by the RecQ-type helicase  
11 Rqh1. *PLoS biology* **12**, e1001968, doi:10.1371/journal.pbio.1001968 (2014).
- 12 13 Gopinathan Nair, A. *et al.* Unorthodox PCNA Binding by Chromatin Assembly Factor 1. *Int J*  
13 *Mol Sci* **23**, doi:10.3390/ijms231911099 (2022).
- 14 14 Kaufman, P. D., Kobayashi, R. & Stillman, B. Ultraviolet radiation sensitivity and reduction of  
15 telomeric silencing in *Saccharomyces cerevisiae* cells lacking chromatin assembly factor-I.  
16 *Genes Dev* **11**, 345-357, doi:10.1101/gad.11.3.345 (1997).
- 17 15 Dohke, K. *et al.* Fission yeast chromatin assembly factor 1 assists in the replication-coupled  
18 maintenance of heterochromatin. *Genes Cells* **13**, 1027-1043, doi:10.1111/j.1365-  
19 2443.2008.01225.x (2008).
- 20 16 Sauer, P. V. *et al.* Insights into the molecular architecture and histone H3-H4 deposition  
21 mechanism of yeast Chromatin assembly factor 1. *eLife* **6**, doi:10.7554/eLife.23474 (2017).
- 22 17 Mattioli, F. *et al.* DNA-mediated association of two histone-bound CAF-1 complexes drives  
23 tetrasome assembly in the wake of DNA replication. *eLife* **6**, doi:10.7554/eLife.22799 (2017).
- 24 18 Sauer, P. V. *et al.* Mechanistic insights into histone deposition and nucleosome assembly by the  
25 chromatin assembly factor-1. *Nucleic acids research*, doi:10.1093/nar/gky823 (2018).
- 26 19 Zhang, K. *et al.* A DNA binding winged helix domain in CAF-1 functions with PCNA to  
27 stabilize CAF-1 at replication forks. *Nucleic acids research* **44**, 5083-5094,  
28 doi:10.1093/nar/gkw106 (2016).
- 29 20 Richet, N. *et al.* Structural insight into how the human helicase subunit MCM2 may act as a  
30 histone chaperone together with ASF1 at the replication fork. *Nucleic acids research* **43**, 1905-  
31 1917, doi:10.1093/nar/gkv021 (2015).
- 32 21 Huang, H. *et al.* A unique binding mode enables MCM2 to chaperone histones H3-H4 at  
33 replication forks. *Nature structural & molecular biology* **22**, 618-626, doi:10.1038/nsmb.3055  
34 (2015).
- 35 22 Ayoub, J., Buonanno, M., Di Fiore, A., De Simone, G. & Monti, S. M. Biochemical and  
36 Structural Insights into the Winged Helix Domain of P150, the Largest Subunit of the Chromatin  
37 Assembly Factor 1. *Int J Mol Sci* **23**, doi:10.3390/ijms23042160 (2022).
- 38 23 Liu, W. H. *et al.* The Cac1 subunit of histone chaperone CAF-1 organizes CAF-1-H3/H4  
39 architecture and tetramerizes histones. *eLife* **5**, doi:10.7554/eLife.18023 (2016).
- 40 24 Ray-Gallet, D. & Almouzni, G. DNA synthesis-dependent and -independent chromatin  
41 assembly pathways in *Xenopus* egg extracts. *Methods Enzymol* **375**, 117-131,  
42 doi:10.1016/s0076-6879(03)75008-3 (2004).
- 43 25 Hardy, J. *et al.* Histone deposition promotes recombination-dependent replication at arrested  
44 forks. *PLoS genetics* **15**, e1008441, doi:10.1371/journal.pgen.1008441 (2019).
- 45 26 Ray-Gallet, D. *et al.* Dynamics of histone H3 deposition in vivo reveal a nucleosome gap-filling  
46 mechanism for H3.3 to maintain chromatin integrity. *Molecular cell* **44**, 928-941,  
47 doi:10.1016/j.molcel.2011.12.006 (2011).
- 48 27 Liu, W. H., Roemer, S. C., Port, A. M. & Churchill, M. E. CAF-1-induced oligomerization of  
49 histones H3/H4 and mutually exclusive interactions with Asf1 guide H3/H4 transitions among  
50 histone chaperones and DNA. *Nucleic acids research* **40**, 11229-11239, doi:10.1093/nar/gks906  
51 (2012).
- 52 28 Mattioli, F., Gu, Y., Balsbaugh, J. L., Ahn, N. G. & Luger, K. The Cac2 subunit is essential for  
53 productive histone binding and nucleosome assembly in CAF-1. *Sci Rep* **7**, 46274,  
54 doi:10.1038/srep46274 (2017).

- 1 29 Kaufman, P. D., Kobayashi, R., Kessler, N. & Stillman, B. The p150 and p60 subunits of  
2 chromatin assembly factor I: a molecular link between newly synthesized histones and DNA  
3 replication. *Cell* **81**, 1105-1114 (1995).
- 4 30 Rosas, R., Aguilar, R. R., Arslanovic, N., Tyler, J. K. & Churchill, M. E. A. A novel Single  
5 Alpha-Helix-DNA-binding domain in CAF-1 promotes gene silencing and DNA damage  
6 survival through tetrasome-length DNA selectivity and spacer function. *bioRxiv*,  
7 doi:10.1101/2022.10.11.511754 (2022).
- 8 31 Rouillon, C. *et al.* CAF-1 deposits newly synthesized histones during DNA replication using  
9 distinct mechanisms on the leading and lagging strands. *Nucleic acids research*,  
10 doi:10.1093/nar/gkad171 (2023).
- 11 32 Mejlvang, J. *et al.* New histone supply regulates replication fork speed and PCNA unloading. *J*  
12 *Cell Biol* **204**, 29-43, doi:10.1083/jcb.201305017 (2014).
- 13 33 Janke, R., King, G. A., Kupiec, M. & Rine, J. Pivotal roles of PCNA loading and unloading in  
14 heterochromatin function. *Proceedings of the National Academy of Sciences of the United States*  
15 *of America* **115**, E2030-E2039, doi:10.1073/pnas.1721573115 (2018).
- 16 34 Thakar, T. *et al.* Ubiquitinated-PCNA protects replication forks from DNA2-mediated  
17 degradation by regulating Okazaki fragment maturation and chromatin assembly. *Nat Commun*  
18 **11**, 2147, doi:10.1038/s41467-020-16096-w (2020).
- 19 35 Bieniossek, C., Imasaki, T., Takagi, Y. & Berger, I. MultiBac: expanding the research toolbox  
20 for multiprotein complexes. *Trends in biochemical sciences* **37**, 49-57,  
21 doi:10.1016/j.tibs.2011.10.005 (2012).
- 22 36 Miele, S. *et al.* The Xer activation factor of TLCPhi expands the possibilities for Xer  
23 recombination. *Nucleic acids research* **50**, 6368-6383, doi:10.1093/nar/gkac429 (2022).
- 24 37 Anderson, M. *et al.* Co-expression as a convenient method for the production and purification  
25 of core histones in bacteria. *Protein Expr Purif* **72**, 194-204, doi:10.1016/j.pep.2010.03.013  
26 (2010).
- 27 38 Wishart, D. S. *et al.* <sup>1</sup>H, <sup>13</sup>C and <sup>15</sup>N chemical shift referencing in biomolecular NMR. *Journal*  
28 *of biomolecular NMR* **6**, 135-140, doi:10.1007/bf00211777 (1995).
- 29 39 Tamiola, K., Acar, B. & Mulder, F. A. Sequence-specific random coil chemical shifts of  
30 intrinsically disordered proteins. *J Am Chem Soc* **132**, 18000-18003, doi:10.1021/ja105656t  
31 (2010).
- 32 40 Wishart, D. S., Bigam, C. G., Holm, A., Hodges, R. S. & Sykes, B. D. (<sup>1</sup>H), (<sup>13</sup>C) and (<sup>15</sup>N)  
33 random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-  
34 neighbor effects. *Journal of biomolecular NMR* **5**, 332, doi:10.1007/BF00211764 (1995).
- 35 41 Shen, Y. *et al.* Consistent blind protein structure generation from NMR chemical shift data.  
36 *Proceedings of the National Academy of Sciences of the United States of America* **105**, 4685-  
37 4690, doi:10.1073/pnas.0800256105 (2008).
- 38 42 Delaglio, F. *et al.* NMRPipe: a multidimensional spectral processing system based on UNIX  
39 pipes. *Journal of biomolecular NMR* **6**, 277-293, doi:10.1007/BF00197809 (1995).
- 40 43 Shen, Y. & Bax, A. Protein backbone chemical shifts predicted from searching a database for  
41 torsion angle and sequence homology. *Journal of biomolecular NMR* **38**, 289-302,  
42 doi:10.1007/s10858-007-9166-6 (2007).
- 43 44 Thureau, A., Roblin, P. & Perez, J. BioSAXS on the SWING beamline at Synchrotron SOLEIL.  
44 *J Appl Crystallogr* **54**, 1698-1710, doi:10.1107/S1600576721008736 (2021).
- 45 45 Girardot, R., Viguier, G., Pérez, J. & Ounsy, M. FOXTROT: a Java-based application to reduce  
46 and analyse SAXS and WAXS piles of 2D data at Synchrotron SOLEIL. *canSAS-VIII* (2015).
- 47 46 Brookes, E., Vachette, P., Rocco, M. & Perez, J. US-SOMO HPLC-SAXS module: dealing with  
48 capillary fouling and extraction of pure component patterns from poorly resolved SEC-SAXS  
49 data. *J Appl Crystallogr* **49**, 1827-1841, doi:10.1107/S1600576716011201 (2016).
- 50 47 Manalastas-Cantos, K. *et al.* ATSAS 3.0: expanded functionality and new tools for small-angle  
51 scattering data analysis. *J Appl Crystallogr* **54**, 343-355, doi:10.1107/S1600576720013412  
52 (2021).
- 53 48 Rudenko, O., Thureau, A. & Perez, J. Evolutionary refinement of the 3D structure of multi-  
54 domain protein complexes from Small Angle X-ray Scattering data. *Proceedings of the 2019*



- 1            *Genetic and Evolutionary Computation Conference Companion (Gecco'19 Companion)*, 401-  
2            402, doi:10.1145/3319619.3322002 (2019).
- 3    49        UniProt, C. UniProt: the universal protein knowledgebase in 2021. *Nucleic acids research* **49**,  
4            D480-D489, doi:10.1093/nar/gkaa1100 (2021).
- 5    50        Steinegger, M. & Soding, J. MMseqs2 enables sensitive protein sequence searching for the  
6            analysis of massive data sets. *Nat Biotechnol* **35**, 1026-1028, doi:10.1038/nbt.3988 (2017).
- 7    51        Mirdita, M. *et al.* ColabFold: making protein folding accessible to all. *Nat Methods* **19**, 679-  
8            682, doi:10.1038/s41592-022-01488-1 (2022).
- 9    52        Steinegger, M. *et al.* HH-suite3 for fast remote homology detection and deep protein annotation.  
10           *BMC Bioinformatics* **20**, 473, doi:10.1186/s12859-019-3019-7 (2019).
- 11   53        Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:  
12            improvements in performance and usability. *Molecular biology and evolution* **30**, 772-780,  
13            doi:10.1093/molbev/mst010 (2013).
- 14   54        Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-  
15            589, doi:10.1038/s41586-021-03819-2 (2021).
- 16   55        Evans, R. *et al.* Protein complex prediction with AlphaFold-Multimer. *BioRxiv*,  
17            doi:10.1101/2021.10.04.463034 (2022).
- 18   56        Leman, J. K. *et al.* Macromolecular modeling and design in Rosetta: recent methods and  
19            frameworks. *Nat Methods*, doi:10.1038/s41592-020-0848-2 (2020).
- 20